PHranceSCa: A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
Sponsor
Hoffmann-La Roche (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT03674112
Collaborator
(none)
160
40
2
45.5
4
0.1
Study Details
Study Description
Brief Summary
This is a Phase II, randomized, multicentre, multinational, open-label, cross-over study in adult patients who have completed neoadjuvant chemotherapy with neoadjuvant pertuzumab and trastuzumab and have undergone surgical treatment of human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. The study will consist of two adjuvant treatment periods: a treatment cross-over period and a treatment continuation period. It will evaluate participant-reported preference for a subcutaneously administered fixed-dose combination formulation (FDC SC) of pertuzumab and trastuzumab compared with intravenously (IV) administered pertuzumab and trastuzumab formulations. The study will also evaluate participant-reported satisfaction with pertuzumab and trastuzumab FDC SC and health-related quality of life outcomes; healthcare professionals' perceptions of time/resource use and convenience of pertuzumab and trastuzumab FDC SC compared with pertuzumab and trastuzumab IV formulations; as well as the safety and efficacy of each study regimen.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Study Type:
Interventional
Actual Enrollment
:
160 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Patients With HER2-Positive Early Breast Cancer
Actual Study Start Date
:
Dec 19, 2018
Actual Primary Completion Date
:
Feb 24, 2020
Anticipated Study Completion Date
:
Oct 5, 2022
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: A: P+H IV Followed by PH FDC SC In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
Drug: Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg pertuzumab and 600 mg trastuzumab is then followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks (Q3W).
Other Names:
Drug: Pertuzumab IV
Pertuzumab will be administered intravenously (IV) as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.
Other Names:
Drug: Trastuzumab IV
Trastuzumab will be administered intravenously (IV) as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
Other Names:
|
| Experimental: B: PH FDC SC Followed by P+H IV In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
Drug: Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg pertuzumab and 600 mg trastuzumab is then followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks (Q3W).
Other Names:
Drug: Pertuzumab IV
Pertuzumab will be administered intravenously (IV) as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.
Other Names:
Drug: Trastuzumab IV
Trastuzumab will be administered intravenously (IV) as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Percentage of Participants by Their Preferred Method of Pertuzumab and Trastuzumab Administration, as Assessed in Question 1 of the Patient Preference Questionnaire (PPQ) [Cycle 6 Day 1 (each cycle is 21 days)]
Question 1 of the Patient Preference Questionnaire (PPQ) asked participants the following question: "All things considered, which method of administration did you prefer?" The three available options for a participant's response were: IV, SC, or No preference. A point estimate with associated exact Clopper-Pearson binomial 95% confidence interval was calculated only for the percentage of participants who preferred PH FDC SC.
Secondary Outcome Measures
- Percentage of Participants by Responses to the Strength of Their Preferred Method of Pertuzumab and Trastuzumab Administration, as Assessed in Question 2 of the Patient Preference Questionnaire (PPQ) [Cycle 6 Day 1 (each cycle is 21 days)]
Question 1 of the Patient Preference Questionnaire (PPQ) was as follows: "All things considered, which method of administration did you prefer?" The available options for a participant's response were IV, SC, or No preference. In Question 2 of the PPQ, participants who reported a preference for one of the two administration routes in Question 1 of the PPQ were asked to rate the strength of their preference (very strong, fairly strong, not very strong).
- Percentage of Responses From Participants to the Two Main Reasons for Their Preferred Method of Pertuzumab and Trastuzumab Administration, as Assessed in Question 3 of the Patient Preference Questionnaire (PPQ) [Cycle 6 Day 1 (each cycle is 21 days)]
In Question 3 of the PPQ, participants who reported a preference for one of the two administration routes in Question 1 of the PPQ were asked to provide the two main reasons for their preference. The five available options for a participant's response were: Feels less emotionally distressing; Requires less time in the clinic; Lower level of injection-site pain; Feels more comfortable during administration; and Other reason.
- Percentage of Participants by Their Level of Satisfaction With the Respective Methods of Administration (IV and SC), Question 1 of the Therapy Administration Satisfaction Questionnaire -Intravenous (TASQ-IV) and -Subcutaneous (TASQ-SC) [Cycle 3 Day 1, Cycle 6 Day 1 (each cycle is 21 days)]
The Therapy Administration Satisfaction Questionnaire (TASQ) is a 12-item, patient-reported questionnaire measuring the impact of each mode of treatment administration (TASQ-IV for IV treatment and TASQ-SC for SC treatment) on five domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction. The TASQ-IV/-SC was administered at treatment Cycles 3 and 6 according to the order of treatment received per arm during the Cross-Over Period. Question 1 of the TASQ-IV/TASQ-SC is one of two items in the Satisfaction domain, with participants providing their answers to the following question: "How satisfied or dissatisfied were you with the IV infusion/SC injection?" The five available options for a participant's response were: very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, and very dissatisfied.
- Mean Scores of the Five Domains of the TASQ-IV and TASQ-SC (Satisfaction, Physical Impact, Psychological Impact, Impact on Activities of Daily Living, and Convenience) to Assess the Impact of IV and SC Routes of Administration [Cycle 3 Day 1, Cycle 6 Day 1 (each cycle is 21 days)]
The TASQ is a 12-item, patient-reported questionnaire measuring the impact of the mode of treatment administration (TASQ-IV for IV treatment and TASQ-SC for SC treatment) on 5 domains: Physical Impact (3 items: Question [Q]2. Pain, Q3. Swelling, Q4. Redness), Psychological Impact (1 item: Q5. Feeling restricted), Impact on Activities of Daily Living (1 item: Q8. Lost/gained time), Convenience (2 items: Q6. Is it convenient?, Q7. Bothered by the amount of time?), and Satisfaction (2 items: Q1. How satisfied or dissatisfied are you with treatment?, Q12: Would you recommend the way you received the treatment?). In addition, 3 questions in the TASQ (Q9, Q10, Q11) are not part of the domains. Responses for the 3 domains that contain more than 1 item were scored from 0 to 100, with a higher score indicating a better outcome. Responses for the 2 domains with 1 item were scored from 1 to 5, with a higher score indicating a better outcome.
- Percentage of Participants by Their Responses to Question 9 of the TASQ-IV and TASQ-SC, Assessing Whether Participants Receiving IV and SC Administration Have as Much Time as They Would Like to Talk to Their Nurse and/or Doctor About Their Illness [Cycle 3 Day 1 and Cycle 6 Day 1 (each cycle is 21 days)]
The TASQ is a 12-item, patient-reported questionnaire measuring the impact of the mode of treatment administration (TASQ-IV for IV treatment and TASQ-SC for SC treatment) on 5 domains. In addition, 3 questions (Q.9-11) are not part of the domains. The TASQ-IV/-SC was administered at treatment Cycles 3 and 6 according to the order of treatment received per arm during the Cross-Over Period. Question 9 asked the participant, "When you receive the IV infusion/SC injection treatment, are you able to talk to your nurse and/or doctor as much as you would like about your illness?" There were five available response options: a) Yes, I had more than enough time to talk to my nurse and/or doctor; b) Yes, but I would have liked more time to talk to my nurse and/or doctor; c) It does not matter to me if I have time to talk to my nurse and/or doctor during my treatment; d) No, I did not have enough time to talk to my nurse and/or doctor; and e) No, I did not talk to my nurse and/or doctor at all.
- Percentage of Participants by Their Responses to Question 10 of the TASQ-IV and TASQ-SC, Assessing Whether IV and SC Administration Have an Impact on the Amount of Time Participants Have to Talk to Their Nurse and/or Doctor About Their Illness [Cycle 3 Day 1 and Cycle 6 Day 1 (each cycle is 21 days)]
The Therapy Administration Satisfaction Questionnaire (TASQ) is a 12-item, patient-reported questionnaire measuring the impact of the mode of treatment administration (TASQ-IV for IV treatment and TASQ-SC for SC treatment) on 5 domains (questions [Q] 1 to 8 and Q12): Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction. In addition, 3 questions in the TASQ-IV/-SC (Q 9-11) are not part of the domains. The TASQ-IV/-SC were administered at treatment Cycles 3 and 6 according to the order of treatment received in each study arm during the Cross-Over Period. Question 10 of the TASQ-IV/-SC asked the participant "Does the IV infusion/SC injection impact the amount of time you have to talk to your nurse and/or doctor about your illness and other concerns?" There were two available options for the participant's response: Yes or No.
- Percentage of Participants by Their Responses to Question 11 of the TASQ-IV and TASQ-SC, Assessing the Participants' Preferred Method for Receiving Cancer Treatment [Cycle 3 Day 1 and Cycle 6 Day 1 (each cycle is 21 days)]
The Therapy Administration Satisfaction Questionnaire (TASQ) is a 12-item, patient-reported questionnaire measuring the impact of the mode of treatment administration (TASQ-IV for IV treatment and TASQ-SC for SC treatment) on 5 domains (questions [Q] 1 to 8 and Q12): Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction. In addition, 3 questions in the TASQ-IV/-SC (Q 9-11) are not part of the domains. The TASQ-IV/-SC was administered at treatment Cycles 3 and 6 according to the order of treatment received during the Cross-Over Period. Question 11 of the TASQ-IV/-SC asked the participant, "There are two ways to get cancer treatment: a) IV infusion given through a port or small tube; b) SC (subcutaneous) injection in your thigh. Which would you prefer?" There were three available options for the participant's response: IV, SC, or No Preference.
- Percentage of Participants by Their Choice of Treatment in the Treatment Continuation Period (PH FDC SC or P+H IV) and by Consistency of This Choice With Their Preferred Method of Administration Reported in Question 1 of the PPQ [Cycle 7 Day 1 (each cycle is 21 days)]
At treatment Cycle 7, participants were expected to select the study treatment formulation (PH FDC SC or P+H IV) to complete their 18 cycles of neo/adjuvant HER2-targeted treatment after completion of the Treatment Cross-over Period. Additionally, for each participant's preference category (SC, IV, and No preference) as per the question 1 of the patient preference questionnaire (PPQ), the percentage of participants who selected each treatment administration route for the Treatment Continuation Period (PH FDC SC or P+H IV) was summarized.
- Duration of Treatment Administration Activities According to Healthcare Professionals' Responses on Perception of Time by Treatment Cycle, Question 1 of the Healthcare Professional Questionnaire (HCPQ) - Treatment Room [Day 1 of Cycles 1-6 (each cycle is 21 days)]
The Healthcare Professional Questionnaire (HCPQ)-Treatment Room Question 1 was completed at each treatment cycle of the Treatment Cross-Over Period by the healthcare professionals (HCPs) who administered treatment to the study's participants. HCPs responded to the following parts of Question 1 that sought to evaluate the amount of time it took to complete activities related to treatment administration: "If new IV access was needed for this cycle of treatment, please indicate what type of IV access was provided (central venous catheter, peripherally inserted central catheter, or peripheral vein cannulation) and how long (in minutes) this took to set up (only for participants receiving IV treatment)? How long (in minutes) did it take to administer the treatment, i.e. total infusion duration? How long (in minutes) was the patient in the Treatment Room for in total?"
- Percentage of Healthcare Professionals (HCPs) by Their Responses on Perception of Impact of PH FDC SC on Clinical Management and Clinical Efficiency, Question 2 of the HCPQ - Treatment Room [Day 1 of Cycle 6 (each cycle is 21 days)]
HCPs who administered study treatment responded at Cycle 6 of the Treatment Cross-Over Period to the following HCPQ-Treatment Room Question 2: "If all P+H IV infusions are switched to FDC SC injections, please indicate how strongly you agree or disagree with each of the following statements: a) Patients will be moved outside of infusion unit to receive FDC SC; b) FDC SC route will allow more flexible scheduling; c) More patients will be treated in the infusion unit; d) Waiting list for any P+H IV treatment at the infusion unit will be reduced; e) Staff resources will be redistributed to other departments of the hospital; f) There will still be sufficient interaction time between HCPs and patients; g) Staff will spend more time for further education/development; h) Staff will dedicate more time attending to administrative tasks for Perjeta-Herceptin patients; i) Patients will spend less time in the care unit; j) Administration by FDC SC injection is preferred by patients."
- Percentage of Healthcare Professionals (HCPs) by Their Responses on Perception of Time/Resource Use and Convenience of Each Study Regimen, Questions 3 to 7 of the HCPQ - Treatment Room [Day 1 of Cycle 6 (each cycle is 21 days)]
Healthcare professionals (HCPs) who administered study treatment responded at Cycle 6 of the Treatment Cross-Over Period to the following HCPQ-Treatment Room Questions 3 to 7: "Looking back over the Perjeta-Herceptin treatment sessions, please indicate based on your opinion which administration method: Q3. Which Method Was Most Convenient for the Patient? Q4. Which Method Was Best for Optimizing Patient Care in Your Centre? Q5. Which Method Took the Least Time from Start to Finish of Administration? Q6. Which Method Required the Least Resource Use for Administration? Q7. Which Method Was Preferred by Patients?" The four available response options were: P+H IV, FDC SC, No Difference, and Unsure.
- Percentage of Healthcare Professionals (HCPs) by Their Responses to Question 8 of the HCPQ - Treatment Room [Day 1 of Cycle 6 (each cycle is 21 days)]
Healthcare professionals (HCPs) who administered study treatment responded at Cycle 6 of the Treatment Cross-Over Period to the following HCPQ-Treatment Room Question 8: "How frequently would you offer or recommend FDC SC administration to your patients in the future?" The three available response options were: Always, Sometimes, and Never.
- Duration of Treatment Preparation According to Healthcare Professionals' Responses on Perception of Time by Treatment Cycle, Question 1 of the HCPQ - Drug Preparation Room [Day 1 of Cycles 1-6 (each cycle is 21 days)]
The Healthcare Professional Questionnaire (HCPQ)-Drug Preparation Room Question 1 was completed at each treatment cycle of the Treatment Cross-Over Period by the healthcare professionals (HCPs) within the pharmacy/drug preparation area where pertuzumab IV and trastuzumab IV and pertuzumab and trastuzumab FDC SC were prepared and dispensed for treating the study's participants. HCPs responded to the following question: "How long (in minutes) did it take to prepare the treatment for use?"
- Percentage of Healthcare Professionals (HCPs) by Their Responses on Perception of Impact of PH FDC SC on Clinical Management and Clinical Efficiency, Question 2 of the HCPQ - Drug Preparation Room [Day 1 of Cycle 6 (each cycle is 21 days)]
Healthcare professionals (HCPs) who prepared study treatment within the pharmacy/drug preparation area responded at Cycle 6 of the Treatment Cross-Over Period to the following HCPQ-Drug Preparation Room Question 2: "If all P+H IV infusions are switched to FDC SC injections, please indicate how strongly you agree or disagree with each of the following statements: a) Staff will have increased availability for other tasks in the pharmacy; b) Administrative procedures around FDC SC will require less time; c) FDC SC formulations will provide more flexibility for staff in managing their workload; d) Due to ready-to-use FDC SC formulations, potential dosing errors will be avoided; e) Due to ready-to-use FDC SC formulations, there will be less drug wastage; f) Without having to reconstitute the drug, less storage space for FDC SC related supplies will be required in the pharmacy; g) Preparation procedures and associated time staff time commitment will be reduced."
- Percentage of Healthcare Professionals (HCPs) by Their Responses on Perception of Time/Resource Use of Each Study Regimen, Questions 3 and 4 of the HCPQ - Drug Preparation Room [Day 1 of Cycle 6 (each cycle is 21 days)]
Healthcare professionals (HCPs) who prepared study treatment within the pharmacy/drug preparation area responded at Cycle 6 of the Treatment Cross-Over Period to the following HCPQ-Drug Preparation Room Questions 3 and 4: "Looking back over the Perjeta-Herceptin treatment sessions, please indicate based on your opinion which administration method: Q3. Was quickest from start to end of preparation to finish of administration (excluding observation period)?; Q4. Required less resource use for preparation and administration, for example nursing time, facility costs, equipment etc?" The three available response options were: P+H IV, FDC SC, and No Difference.
- Change From Baseline Over Time in Health-Related Quality of Life (HRQoL) as Assessed by the Global Health Status/QoL Scale Score of the the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC QLQ-C30) [Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years)]
- Change From Baseline Over Time in the Physical Functioning Scale Score of the EORTC QLQ-C30 [Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years)]
- Change From Baseline Over Time in the Role Functioning Scale Score of the EORTC QLQ-C30 [Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years)]
- Change From Baseline Over Time in the Emotional Functioning Scale Score of the EORTC QLQ-C30 [Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years)]
- Change From Baseline Over Time in the Cognitive Functioning Scale Score of the EORTC QLQ-C30 [Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years)]
- Change From Baseline Over Time in the Social Functioning Scale Score of the EORTC QLQ-C30 [Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years)]
- Change From Baseline Over Time in the Fatigue Scale Score of the EORTC QLQ-C30 [Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years)]
- Change From Baseline Over Time in the Nausea and Vomiting Scale Score of the EORTC QLQ-C30 [Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years)]
- Change From Baseline Over Time in the Pain Scale Score of the EORTC QLQ-C30 [Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years)]
- Change From Baseline Over Time in the Dyspnoea Scale Score of the EORTC QLQ-C30 [Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years)]
- Change From Baseline Over Time in the Insomnia Scale Score of the EORTC QLQ-C30 [Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years)]
- Change From Baseline Over Time in the Appetite Loss Scale Score of the EORTC QLQ-C30 [Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years)]
- Change From Baseline Over Time in the Constipation Scale Score of the EORTC QLQ-C30 [Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years)]
- Change From Baseline Over Time in the Diarrhoea Scale Score of the EORTC QLQ-C30 [Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years)]
- Change From Baseline Over Time in the Financial Difficulties Scale Score of the EORTC QLQ-C30 [Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years)]
- Safety Summary for Assessment of Switching Between the FDC SC and IV Formulations: Number of Participants With at Least One Adverse Event During the Treatment Cross-Over Period by Study Arm and Treatment Received [From Day 1 of Cycle 1 to the end of Cycle 3 of Cross-Over Period; from Day 1 of Cycle 4 to the end of Cycle 6 of Cross-Over Period (1 cycle is 21 days)]
Investigators used the NCI CTCAE v4.0 grading scale for assessing adverse event (AE) severity; if not listed, AE severity was graded as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe or medically significant; Grade 4 = life-threatening; Grade 5 = death related to AE. Severity and seriousness are not synonymous and investigators independently assessed these criteria for each AE. Investigators also determined whether an AE was considered to be related to the study drug. Adverse events to monitor were defined based on known risks associated with the study drugs and included: hypersensitivity reactions, administration-related reactions (ARRs), cardiac dysfunction, diarrhea grade ≥3, rash/skin reactions, mucositis, interstitial lung disease (ILD), (febrile) neutropenia, pulmonary events that may occur as a result of an ARR, and pregnancy/neonatal related. Multiple occurrences of AEs were counted only once per participant. LVEF = left ventricular ejection fraction
- Safety Summary of the FDC SC and IV Formulations: Number of Participants With at Least One Adverse Event During the Treatment Cross-Over and Treatment Continuation Periods [From Day 1 of Cycle 1 of the Treatment Cross-Over Period up to the completion of 18 cycles of neo/adjuvant anti-HER2 treatment in the Treatment Continuation Period (1 cycle is 21 days)]
Investigators used the NCI CTCAE v4.0 grading scale for assessing adverse event (AE) severity; if not listed, AE severity was graded as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe or medically significant; Grade 4 = life-threatening; Grade 5 = death related to AE. Severity and seriousness are not synonymous and investigators independently assessed these criteria for each AE. Investigators also determined whether an AE was considered to be related to the study drug. Adverse events to monitor were defined based on known risks associated with the study drugs and included: hypersensitivity reactions, administration-related reactions (ARRs), cardiac dysfunction, diarrhea grade ≥3, rash/skin reactions, mucositis, interstitial lung disease (ILD), (febrile) neutropenia, pulmonary events that may occur as a result of an ARR, and pregnancy/neonatal related. Multiple occurrences of AEs were counted only once per participant. LVEF = left ventricular ejection fraction
- Number of Participants With at Least One Event of Heart Failure With the FDC SC and IV Formulations During the Treatment Cross-Over and Treatment Continuation Periods [From Day 1 of Cycle 1 of the Treatment Cross-Over Period up to the completion of 18 cycles of neo/adjuvant anti-HER2 treatment in the Treatment Continuation Period (1 cycle is 21 days)]
Heart failure is defined as a disorder characterized by the inability of the heart to pump blood at an adequate volume to meet tissue metabolic requirements, or, the ability to do only at an elevation in the filling pressure. Any adverse event of symptomatic left ventricular systolic dysfunction (LVSD; also referred to as heart failure) occurring during the study was to be reported as a serious adverse event.
- Number of Participants With at Least One Event of Ejection Fraction Decreased With the FDC SC and IV Formulations During the Treatment Cross-Over and Treatment Continuation Periods [Baseline; Day 1 of Cycles 4, 7, and 11 (each cycle is 21 days); End of Treatment and Follow-Up visits (up to 3 years)]
Left ventricular ejection fraction (LVEF) is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. All participants who enrolled in this study must have had a baseline LVEF ≥55%. Verbatim description of adverse events was mapped to Medical Dictionary for Regulatory Activities (MedDRA) version 22.1. The MedDRA preferred term of 'ejection fraction decreased' is defined as an LVEF decrease of at least 10 percentage points from baseline and to below 50%.
- Number of Participants With Targeted Vital Signs Outside the Normal Limits During the Treatment Cross-Over Period Among Those Without an Abnormality at Baseline [Pre-dose at Day 1 of Cycles 1 (baseline), 4, and 7 (1 cycle is 21 days)]
The number of participants at any post-baseline timepoint with abnormal readings outside the normal range for vital signs of diastolic and systolic blood pressure, pulse rate, respiratory rate, and body temperature were summarized according the specified direction of the abnormal reading (high or low). The number analyzed (denominator) in the results table represents participants without the specified abnormal vital sign at baseline. Not every vital sign abnormality qualified as an adverse event (AE). A vital sign result must have been reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation); resulted in a medical intervention or a change in concomitant therapy; or, was clinically significant in the investigator's judgment.
- Number of Participants With Chemistry and Hematology Laboratory Test Result Shifts From NCI-CTCAE Grade 0-2 at Baseline to Grade 3-4 Post-Baseline During the Treatment Cross-Over Period [Pre-dose at Day 1 of Cycles 1 (baseline), 4, and 7 (1 cycle is 21 days)]
Laboratory data for targeted chemistry and hematology parameters were classified according to the NCI CTCAE v4.0; Grade 0 is normal and Grades 1 to 4 represent worsening levels of the parameter outside of the normal range in the specified direction of the abnormality (high and low are above and below the range, respectively). The results show the shifts in the number of participants with Grade 0-2 at baseline to Grade 3-4 post-baseline; those with missing baseline values were counted as Grade 0-2 at baseline. Not every laboratory abnormality qualified as an adverse event, only if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation); resulted in a medical intervention or a change in concomitant therapy; or, was clinically significant in the investigator's judgment. SGOT/AST = aspartate aminotransferase; SGPT/ALT = alanine aminotransferase
- Kaplan-Meier Estimate of the Percentage of Participants in Overall Survival [Up to 3 years]
- Kaplan-Meier Estimate of the Percentage of Participants in Invasive Disease-Free Survival Including Second Primary Non-Breast Cancer [Up to 3 years]
- Kaplan-Meier Estimate of the Percentage of Participants in Invasive Disease-Free Survival [Up to 3 years]
- Kaplan-Meier Estimate of the Percentage of Participants in Distant Disease-Free Survival [Up to 3 years]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
Disease-specific criteria:
-
Female or male with histologically confirmed, HER2-positive (HER2+) inflammatory, locally advanced or early-stage breast cancer who have received neoadjuvant pertuzumab and trastuzumab and have completed neoadjuvant chemotherapy and subsequently undergone surgery for their breast cancer.
-
HER2+ breast cancer assessed at the local laboratory prior to initiation of neoadjuvant therapy. HER2+ status must be determined based on breast biopsy material obtained prior to neoadjuvant treatment and is defined as 3+ by immunohistochemistry (IHC) and/or positive by HER2 amplification by in situ hybridization (ISH) with a ratio of ≥2 for the number of HER2 gene copies to the number of chromosome 17 copies.
-
Hormone receptor status of the primary tumour determined by local assessment. Hormone receptor status may be either positive or negative.
-
Completed all neoadjuvant chemotherapy and surgery. Adjuvant radiotherapy may be planned or ongoing at study entry and adjuvant hormone therapy is allowed during the study. Note that study treatment cannot be initiated within <2 weeks of surgery but must be initiated ≤9 weeks from the last administration of systemic neoadjuvant therapy.
-
No evidence of residual, locally recurrent or metastatic disease after completion of surgery. Patients with clinical suspicion of metastases must undergo radiological assessments per institutional practice to rule out distant disease.
-
Wound healing after breast cancer surgery adequate per investigator's assessment to allow initiation of study treatment within ≤9 weeks of last systemic neoadjuvant therapy
-
No adjuvant chemotherapy planned. Note that adjuvant hormonal treatment is allowed during the study.
General criteria:
-
Ability to comply with the study protocol, in the investigator's judgment
-
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
-
Intact skin at planned site of subcutaneous injections (thigh)
-
Left ventricular ejection fraction (LVEF) ≥55% measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan within 28 days of study randomization
-
No major surgical procedure unrelated to breast cancer within 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment
-
For women of childbearing potential: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating eggs, Women must remain abstinent or use non-hormonal contraceptive methods with a failure rate of <1% per year, or two effective non-hormonal contraceptive methods during the study treatment periods and for 7 months after the last dose of study treatment
-
For men: agreement to remain abstinent or use a condom, and agreement to refrain from donating sperm, men must remain abstinent or use a condom during the study treatment periods and for seven months after the last dose of study treatment to avoid exposing the embryo. Men must refrain from donating sperm during this same period
-
A negative serum pregnancy test must be available prior to randomization for women of childbearing potential
Exclusion Criteria:
Cancer-specific criteria:
-
Stage IV (metastatic) breast cancer
-
Current or prior history of active malignancy within the last five years. Appropriately treated non-melanoma skin cancer; in situ carcinomas, including cervix, colon, or skin; or Stage I uterine cancer within the last five years are allowed
-
Previous systemic therapy for treatment or prevention of breast cancer, except neoadjuvant Perjeta, Herceptin and chemotherapy for current breast cancer
General criteria:
-
Investigational treatment within four weeks of enrolment
-
Serious cardiac illness or medical conditions
-
History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias, such as structural heart disease, coronary heart disease, clinically significant electrolyte abnormalities, or family history of sudden unexplained death or long QT syndrome
-
Inadequate bone marrow, renal and impaired liver function
-
Current severe, uncontrolled systemic disease that may interfere with planned treatment
-
Pregnant or breastfeeding, or intending to become pregnant during the study or within seven months after the last dose of study treatment. Women of childbearing potential must have a negative serum pregnancy test result within seven days prior to initiation of study treatment
-
Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in, and completion of, the study
-
Known active liver disease, for example, active viral hepatitis infection, autoimmune hepatic disorders, or sclerosing cholangitis
-
Concurrent, serious, uncontrolled infections, or known infection with human immunodeficiency virus (HIV)
-
Known hypersensitivity to any of the study drugs, excipients, and/or murine proteins
-
Current chronic daily treatment with corticosteroids
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Rocky Mountain Cancer Center - Lakewood (West) | Lakewood | Colorado | United States | 80228 |
| 2 | Illinois Cancer Care | Peoria | Illinois | United States | 61615 |
| 3 | Cancer Center of Kansas | Wichita | Kansas | United States | 67214-3728 |
| 4 | Maryland Oncology Hematology | Rockville | Maryland | United States | 20850 |
| 5 | Texas Oncology - Dallas Presbyterian Hospital | Dallas | Texas | United States | 75231 |
| 6 | Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | United States | 75246 |
| 7 | Texas Oncology - Memorial City | Houston | Texas | United States | 77024 |
| 8 | USOR - Texas Oncology - San Antonio Northeast | San Antonio | Texas | United States | 78217 |
| 9 | Texas Oncology, P.A. - Tyler; Tyler Cancer Center | Tyler | Texas | United States | 75702 |
| 10 | Hospital Britanico de Buenos Aires | Ciudad Autonoma Buenos Aires | Argentina | C1284AEB | |
| 11 | Instituto de Câncer E Transplante | Curitiba | PR | Brazil | 80510-130 |
| 12 | Clinicas Oncologicas Integradas - COI | Rio De Janeiro | RJ | Brazil | 22290-160 |
| 13 | Instituto de Ensino e Pesquisa Sao Lucas - IEP | Sao Paulo | SP | Brazil | 01236-030 |
| 14 | Núcleo de Pesquisa São Camilo; ONCOLOGIA CLINICA / QUIMIOTERAPIA | Sao Paulo | SP | Brazil | 04014-002 |
| 15 | Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas | Recoleta | Chile | 8420383 | |
| 16 | Hospital Hermanos Ameijeiras | La Habana | Cuba | 10300 | |
| 17 | Instituto Nacional de Oncología y Radiología (INOR) | La Habana | Cuba | 10400 | |
| 18 | KYS Sadesairaala; Syopatautien poliklinikka | Kuopio | Finland | 70210 | |
| 19 | VAASAN KESKUSSAIRAALA; Onkologian poliklinikka | Vaasa | Finland | 65130 | |
| 20 | Princess Margaret Hospital, Oncology; Department of Oncology | Hong Kong | Hong Kong | ||
| 21 | Prince of Wales Hosp; Dept. Of Clinical Onc | Shatin | Hong Kong | ||
| 22 | King Hussein Cancer Center | Amman | Jordan | 1269 | |
| 23 | Bellevue Medical Center | El-Metn | Lebanon | 2241 | |
| 24 | Hammoud Hospital | Saida | Lebanon | 6520 | |
| 25 | Consultorio Privado (José Luis González Trujillo) | Leon | Guanajuato | Mexico | |
| 26 | Centro Médico Zambrano Hellion | Monterrey | Nuevo LEON | Mexico | 66278 |
| 27 | Cuidados oncologicos | Querétaro | Queretaro | Mexico | 76000 |
| 28 | Centro Oncológico de Panamá | Panama | Panama | 0801 | |
| 29 | Centro Hemato Oncologico Panama | Panama | Panama | 0832 | |
| 30 | Hospital da Luz; Departamento de Oncologia Medica | Lisboa | Portugal | 1500-650 | |
| 31 | Hospital de Santa Maria; Servico de Oncologia Medica | Lisboa | Portugal | 1649-035 | |
| 32 | IPO do Porto; Servico de Oncologia Medica | Porto | Portugal | 4200-072 | |
| 33 | National Center for Cancer Care and Research | Doha | Qatar | 15054 | |
| 34 | King Fahad Medical City; Gastroentrology | Riyadh | Saudi Arabia | 11525 | |
| 35 | Institute of Oncology and Radiology of Serbia | Belgrade | Serbia | 11000 | |
| 36 | Clinical Centre Nis, Clinic for Oncology | Nis | Serbia | 18000 | |
| 37 | Hospital General Universitario de Elche; Servicio de Oncologia | Elche | Alicante | Spain | 03203 |
| 38 | Hospital Universitario de Canarias;servicio de Oncologia | La Laguna | Tenerife | Spain | 38320 |
| 39 | Sodersjukhuset; Onkologkliniken | Stockholm | Sweden | 118 83 | |
| 40 | Västmanlands sjukhus Västerås, Onkologkliniken | Västerås | Sweden | 72189 |
Sponsors and Collaborators
- Hoffmann-La Roche
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study Documents (Full-Text)
More Information
Publications
None provided.Responsible Party:
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT03674112
Other Study ID Numbers:
- MO40628
- 2018-002153-30
First Posted:
Sep 17, 2018
Last Update Posted:
Apr 5, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail | A total of 183 patients were screened and 160 participants were enrolled. |
| Arm/Group Title | A: P+H IV Followed by PH FDC SC | B: PH FDC SC Followed by P+H IV |
|---|---|---|
| Arm/Group Description | In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
| Period Title: Overall Study | ||
| STARTED | 80 | 80 |
| Completed Cross-Over Treatment (Cycles 1 to 6) | 80 | 80 |
| Completed Continuation Treatment (Cycles 7 up to 18 Total) | 34 | 36 |
| Completed Post-Treatment Follow-Up (Up to 3 Years) | 0 | 0 |
| COMPLETED | 0 | 0 |
| NOT COMPLETED | 80 | 80 |
Baseline Characteristics
| Arm/Group Title | A: P+H IV Followed by PH FDC SC | B: PH FDC SC Followed by P+H IV | Total |
|---|---|---|---|
| Arm/Group Description | In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | Total of all reporting groups |
| Overall Participants | 80 | 80 | 160 |
| Age (Years) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [Years] |
49.4
(11.6)
|
48.2
(12.1)
|
48.8
(11.8)
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
80
100%
|
80
100%
|
160
100%
|
| Male |
0
0%
|
0
0%
|
0
0%
|
| Ethnicity (NIH/OMB) (Count of Participants) | |||
| Hispanic or Latino |
17
21.3%
|
21
26.3%
|
38
23.8%
|
| Not Hispanic or Latino |
59
73.8%
|
54
67.5%
|
113
70.6%
|
| Unknown or Not Reported |
4
5%
|
5
6.3%
|
9
5.6%
|
| Race (NIH/OMB) (Count of Participants) | |||
| American Indian or Alaska Native |
5
6.3%
|
3
3.8%
|
8
5%
|
| Asian |
8
10%
|
4
5%
|
12
7.5%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
| Black or African American |
2
2.5%
|
2
2.5%
|
4
2.5%
|
| White |
62
77.5%
|
67
83.8%
|
129
80.6%
|
| More than one race |
0
0%
|
0
0%
|
0
0%
|
| Unknown or Not Reported |
3
3.8%
|
4
5%
|
7
4.4%
|
| Baseline Weight (kilograms (kg)) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [kilograms (kg)] |
67.36
(12.08)
|
70.21
(14.15)
|
68.78
(13.20)
|
| Eastern Cooperative Oncology Group (ECOG) Performance Status at Baseline (Count of Participants) | |||
| ECOG Peformance Status 0 |
70
87.5%
|
70
87.5%
|
140
87.5%
|
| ECOG Peformance Status 1 |
10
12.5%
|
10
12.5%
|
20
12.5%
|
| Number of Cycles of Prior Neoadjuvant Pertuzumab IV and Trastuzumab IV (Count of Participants) | |||
| <4 Cycles |
5
6.3%
|
10
12.5%
|
15
9.4%
|
| ≥4 Cycles |
75
93.8%
|
70
87.5%
|
145
90.6%
|
| Prior Neoadjuvant Chemotherapy Regimen (Count of Participants) | |||
| Anthracyclines + Taxanes |
55
68.8%
|
53
66.3%
|
108
67.5%
|
| Carboplatin + Taxanes |
22
27.5%
|
23
28.8%
|
45
28.1%
|
| Taxanes Only |
3
3.8%
|
4
5%
|
7
4.4%
|
| Pathological Complete Response (pCR) to Prior Neoadjuvant Treatment (Count of Participants) | |||
| pCR |
52
65%
|
50
62.5%
|
102
63.8%
|
| Non-pCR |
28
35%
|
30
37.5%
|
58
36.3%
|
| Hormone Receptor Status (Count of Participants) | |||
| Estrogen Receptor (ER)-Positive and/or Progesterone Receptor (PgR)-Positive |
53
66.3%
|
51
63.8%
|
104
65%
|
| ER-Negative and PgR-Negative |
27
33.8%
|
29
36.3%
|
56
35%
|
Outcome Measures
| Title | Percentage of Participants by Their Preferred Method of Pertuzumab and Trastuzumab Administration, as Assessed in Question 1 of the Patient Preference Questionnaire (PPQ) |
|---|---|
| Description | Question 1 of the Patient Preference Questionnaire (PPQ) asked participants the following question: "All things considered, which method of administration did you prefer?" The three available options for a participant's response were: IV, SC, or No preference. A point estimate with associated exact Clopper-Pearson binomial 95% confidence interval was calculated only for the percentage of participants who preferred PH FDC SC. |
| Time Frame | Cycle 6 Day 1 (each cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Modified Intent-to-Treat (mITT) Population: All randomized participants, allocated to their randomized treatment arm, who received at least one dose by both SC and IV routes of administration during the Treatment Cross-over Period and subsequently answered at least Question 1 of the PPQ. |
| Arm/Group Title | All Participants | A: P+H IV Followed by PH FDC SC | B: PH FDC SC Followed by P+H IV |
|---|---|---|---|
| Arm/Group Description | In the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
| Measure Participants | 160 | 80 | 80 |
| SC Preference |
85.00
106.3%
|
87.50
109.4%
|
82.50
51.6%
|
| IV Preference |
13.8
17.3%
|
12.5
15.6%
|
15.0
9.4%
|
| No Preference |
1.3
1.6%
|
0.0
0%
|
2.5
1.6%
|
| Title | Percentage of Participants by Responses to the Strength of Their Preferred Method of Pertuzumab and Trastuzumab Administration, as Assessed in Question 2 of the Patient Preference Questionnaire (PPQ) |
|---|---|
| Description | Question 1 of the Patient Preference Questionnaire (PPQ) was as follows: "All things considered, which method of administration did you prefer?" The available options for a participant's response were IV, SC, or No preference. In Question 2 of the PPQ, participants who reported a preference for one of the two administration routes in Question 1 of the PPQ were asked to rate the strength of their preference (very strong, fairly strong, not very strong). |
| Time Frame | Cycle 6 Day 1 (each cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Modified ITT (mITT) Population; for Question 2 of the PPQ, the number analyzed for the strength of SC or IV preference represents the participants who indicated in their responses to Question 1 of the PPQ that they preferred the SC or IV route of administration, respectively. |
| Arm/Group Title | All Participants | A: P+H IV Followed by PH FDC SC | B: PH FDC SC Followed by P+H IV |
|---|---|---|---|
| Arm/Group Description | In the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
| Measure Participants | 158 | 80 | 78 |
| SC Preference: Very Strong |
67.6
84.5%
|
68.6
85.8%
|
66.7
41.7%
|
| SC Preference: Fairly Strong |
25.0
31.3%
|
24.3
30.4%
|
25.8
16.1%
|
| SC Preference: Not Very Strong |
7.4
9.3%
|
7.1
8.9%
|
7.6
4.8%
|
| IV Preference: Very Strong |
54.5
68.1%
|
40.0
50%
|
66.7
41.7%
|
| IV Preference: Fairly Strong |
9.1
11.4%
|
10.0
12.5%
|
8.3
5.2%
|
| IV Preference: Not Very Strong |
36.4
45.5%
|
50.0
62.5%
|
25.0
15.6%
|
| Title | Percentage of Responses From Participants to the Two Main Reasons for Their Preferred Method of Pertuzumab and Trastuzumab Administration, as Assessed in Question 3 of the Patient Preference Questionnaire (PPQ) |
|---|---|
| Description | In Question 3 of the PPQ, participants who reported a preference for one of the two administration routes in Question 1 of the PPQ were asked to provide the two main reasons for their preference. The five available options for a participant's response were: Feels less emotionally distressing; Requires less time in the clinic; Lower level of injection-site pain; Feels more comfortable during administration; and Other reason. |
| Time Frame | Cycle 6 Day 1 (each cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Modified ITT (mITT) Population; for Question 3, the number analyzed for the two main reasons for SC or IV preference represents the participants who indicated in their responses to Question 1 of the PPQ that they preferred the SC or IV route of administration, respectively. |
| Arm/Group Title | All Participants | A: P+H IV Followed by PH FDC SC | B: PH FDC SC Followed by P+H IV |
|---|---|---|---|
| Arm/Group Description | In the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
| Measure Participants | 158 | 80 | 78 |
| Measure Responses | 324 | 160 | 164 |
| SC Preference: Feels Less Emotionally Distressing |
16.3
|
14.7
|
18.0
|
| SC Preference: Requires Less Time in the Clinic |
42.2
|
42.0
|
42.4
|
| SC Preference: Lower Level of Injection-Site Pain |
11.3
|
9.8
|
12.9
|
| SC Preference: Feels More Comfortable During Administration |
25.9
|
28.7
|
23.0
|
| SC Preference: Other Reason |
4.3
|
4.9
|
3.6
|
| IV Preference: Feels Less Emotionally Distressing |
16.7
|
17.6
|
16.0
|
| IV Preference: Requires Less Time in the Clinic |
4.8
|
5.9
|
4.0
|
| IV Preference: Lower Level of Injection-Site Pain |
26.2
|
23.5
|
28.0
|
| IV Preference: Feels More Comfortable During Administration |
33.3
|
47.1
|
24.0
|
| IV Preference: Other Reason |
19.0
|
5.9
|
28.0
|
| Title | Percentage of Participants by Their Level of Satisfaction With the Respective Methods of Administration (IV and SC), Question 1 of the Therapy Administration Satisfaction Questionnaire -Intravenous (TASQ-IV) and -Subcutaneous (TASQ-SC) |
|---|---|
| Description | The Therapy Administration Satisfaction Questionnaire (TASQ) is a 12-item, patient-reported questionnaire measuring the impact of each mode of treatment administration (TASQ-IV for IV treatment and TASQ-SC for SC treatment) on five domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction. The TASQ-IV/-SC was administered at treatment Cycles 3 and 6 according to the order of treatment received per arm during the Cross-Over Period. Question 1 of the TASQ-IV/TASQ-SC is one of two items in the Satisfaction domain, with participants providing their answers to the following question: "How satisfied or dissatisfied were you with the IV infusion/SC injection?" The five available options for a participant's response were: very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, and very dissatisfied. |
| Time Frame | Cycle 3 Day 1, Cycle 6 Day 1 (each cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Modified Intent-to-Treat (mITT) Population |
| Arm/Group Title | All Participants: TASQ-IV Completers | All Participants: TASQ-SC Completers |
|---|---|---|
| Arm/Group Description | This analysis set includes all participants from Arms A and B who completed the TASQ-IV questionnaire, which was administered at the last IV treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | This analysis set includes all participants from Arms A and B who completed the TASQ-SC questionnaire, which was administered at the last SC treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
| Measure Participants | 160 | 160 |
| Very Satisfied |
25.6
32%
|
57.5
71.9%
|
| Satisfied |
41.9
52.4%
|
30.6
38.3%
|
| Neither Satisfied nor Dissatisfied |
25.6
32%
|
4.4
5.5%
|
| Dissatisfied |
5.6
7%
|
1.9
2.4%
|
| Very Dissatisfied |
1.3
1.6%
|
4.4
5.5%
|
| Did Not Answer Question |
0.0
0%
|
1.3
1.6%
|
| Title | Mean Scores of the Five Domains of the TASQ-IV and TASQ-SC (Satisfaction, Physical Impact, Psychological Impact, Impact on Activities of Daily Living, and Convenience) to Assess the Impact of IV and SC Routes of Administration |
|---|---|
| Description | The TASQ is a 12-item, patient-reported questionnaire measuring the impact of the mode of treatment administration (TASQ-IV for IV treatment and TASQ-SC for SC treatment) on 5 domains: Physical Impact (3 items: Question [Q]2. Pain, Q3. Swelling, Q4. Redness), Psychological Impact (1 item: Q5. Feeling restricted), Impact on Activities of Daily Living (1 item: Q8. Lost/gained time), Convenience (2 items: Q6. Is it convenient?, Q7. Bothered by the amount of time?), and Satisfaction (2 items: Q1. How satisfied or dissatisfied are you with treatment?, Q12: Would you recommend the way you received the treatment?). In addition, 3 questions in the TASQ (Q9, Q10, Q11) are not part of the domains. Responses for the 3 domains that contain more than 1 item were scored from 0 to 100, with a higher score indicating a better outcome. Responses for the 2 domains with 1 item were scored from 1 to 5, with a higher score indicating a better outcome. |
| Time Frame | Cycle 3 Day 1, Cycle 6 Day 1 (each cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Modified Intent-to-Treat (mITT) Population; The number analyzed indicates the number of participants who completed the TASQ-IV/-SC questionnaire items within a domain. |
| Arm/Group Title | All Participants: TASQ-IV Completers | All Participants: TASQ-SC Completers |
|---|---|---|
| Arm/Group Description | This analysis set includes all participants from Arms A and B who completed the TASQ-IV questionnaire, which was administered at the last IV treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | This analysis set includes all participants from Arms A and B who completed the TASQ-SC questionnaire, which was administered at the last SC treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
| Measure Participants | 160 | 160 |
| Satisfaction Domain |
64.3
(23.6)
|
87.7
(17.5)
|
| Physical Impact Domain |
86.5
(14.8)
|
81.3
(15.4)
|
| Psychological Impact Domain |
3.8
(1.2)
|
4.6
(0.7)
|
| Impact on Activities of Daily Living Domain |
2.3
(0.9)
|
3.9
(1.0)
|
| Convenience Domain |
56.8
(26.0)
|
90.0
(13.8)
|
| Title | Percentage of Participants by Their Responses to Question 9 of the TASQ-IV and TASQ-SC, Assessing Whether Participants Receiving IV and SC Administration Have as Much Time as They Would Like to Talk to Their Nurse and/or Doctor About Their Illness |
|---|---|
| Description | The TASQ is a 12-item, patient-reported questionnaire measuring the impact of the mode of treatment administration (TASQ-IV for IV treatment and TASQ-SC for SC treatment) on 5 domains. In addition, 3 questions (Q.9-11) are not part of the domains. The TASQ-IV/-SC was administered at treatment Cycles 3 and 6 according to the order of treatment received per arm during the Cross-Over Period. Question 9 asked the participant, "When you receive the IV infusion/SC injection treatment, are you able to talk to your nurse and/or doctor as much as you would like about your illness?" There were five available response options: a) Yes, I had more than enough time to talk to my nurse and/or doctor; b) Yes, but I would have liked more time to talk to my nurse and/or doctor; c) It does not matter to me if I have time to talk to my nurse and/or doctor during my treatment; d) No, I did not have enough time to talk to my nurse and/or doctor; and e) No, I did not talk to my nurse and/or doctor at all. |
| Time Frame | Cycle 3 Day 1 and Cycle 6 Day 1 (each cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Modified Intent-to-Treat (mITT) Population |
| Arm/Group Title | All Participants: TASQ-IV Completers | All Participants: TASQ-SC Completers |
|---|---|---|
| Arm/Group Description | This analysis set includes all participants from Arms A and B who completed the TASQ-IV questionnaire, which was administered at the last IV treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | This analysis set includes all participants from Arms A and B who completed the TASQ-SC questionnaire, which was administered at the last SC treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
| Measure Participants | 160 | 160 |
| a) Yes, I had enough time to talk to my nurse and/or doctor |
82.5
103.1%
|
90.0
112.5%
|
| b) Yes, but I would have liked more time to talk to my nurse and/or doctor |
9.4
11.8%
|
5.0
6.3%
|
| c) It does not matter to me if I have time to talk to my nurse and/or doctor |
5.0
6.3%
|
3.1
3.9%
|
| d) No, I did not have enough time to talk to my nurse and/or doctor |
0.6
0.8%
|
0.6
0.8%
|
| e) No, I did not talk to my nurse and/or doctor at all |
2.5
3.1%
|
0.0
0%
|
| Patient did not answer question |
0.0
0%
|
1.3
1.6%
|
| Title | Percentage of Participants by Their Responses to Question 10 of the TASQ-IV and TASQ-SC, Assessing Whether IV and SC Administration Have an Impact on the Amount of Time Participants Have to Talk to Their Nurse and/or Doctor About Their Illness |
|---|---|
| Description | The Therapy Administration Satisfaction Questionnaire (TASQ) is a 12-item, patient-reported questionnaire measuring the impact of the mode of treatment administration (TASQ-IV for IV treatment and TASQ-SC for SC treatment) on 5 domains (questions [Q] 1 to 8 and Q12): Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction. In addition, 3 questions in the TASQ-IV/-SC (Q 9-11) are not part of the domains. The TASQ-IV/-SC were administered at treatment Cycles 3 and 6 according to the order of treatment received in each study arm during the Cross-Over Period. Question 10 of the TASQ-IV/-SC asked the participant "Does the IV infusion/SC injection impact the amount of time you have to talk to your nurse and/or doctor about your illness and other concerns?" There were two available options for the participant's response: Yes or No. |
| Time Frame | Cycle 3 Day 1 and Cycle 6 Day 1 (each cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Modified Intent-to-Treat (mITT) Population |
| Arm/Group Title | All Participants: TASQ-IV Completers | All Participants: TASQ-SC Completers |
|---|---|---|
| Arm/Group Description | This analysis set includes all participants from Arms A and B who completed the TASQ-IV questionnaire, which was administered at the last IV treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | This analysis set includes all participants from Arms A and B who completed the TASQ-SC questionnaire, which was administered at the last SC treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
| Measure Participants | 160 | 160 |
| Yes |
20.0
25%
|
13.1
16.4%
|
| No |
79.4
99.3%
|
85.0
106.3%
|
| Patient Did Not Answer Question |
0.6
0.8%
|
1.9
2.4%
|
| Title | Percentage of Participants by Their Responses to Question 11 of the TASQ-IV and TASQ-SC, Assessing the Participants' Preferred Method for Receiving Cancer Treatment |
|---|---|
| Description | The Therapy Administration Satisfaction Questionnaire (TASQ) is a 12-item, patient-reported questionnaire measuring the impact of the mode of treatment administration (TASQ-IV for IV treatment and TASQ-SC for SC treatment) on 5 domains (questions [Q] 1 to 8 and Q12): Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction. In addition, 3 questions in the TASQ-IV/-SC (Q 9-11) are not part of the domains. The TASQ-IV/-SC was administered at treatment Cycles 3 and 6 according to the order of treatment received during the Cross-Over Period. Question 11 of the TASQ-IV/-SC asked the participant, "There are two ways to get cancer treatment: a) IV infusion given through a port or small tube; b) SC (subcutaneous) injection in your thigh. Which would you prefer?" There were three available options for the participant's response: IV, SC, or No Preference. |
| Time Frame | Cycle 3 Day 1 and Cycle 6 Day 1 (each cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Modified Intent-to-Treat (mITT) Population |
| Arm/Group Title | All Participants: TASQ-IV Completers | All Participants: TASQ-SC Completers |
|---|---|---|
| Arm/Group Description | This analysis set includes all participants from Arms A and B who completed the TASQ-IV questionnaire, which was administered at the last IV treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | This analysis set includes all participants from Arms A and B who completed the TASQ-SC questionnaire, which was administered at the last SC treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
| Measure Participants | 160 | 160 |
| Prefer IV Method |
11.9
14.9%
|
9.4
11.8%
|
| Prefer SC Method |
70.6
88.3%
|
82.5
103.1%
|
| No Preference |
11.9
14.9%
|
5.6
7%
|
| Patient Did Not Answer Question |
5.6
7%
|
2.5
3.1%
|
| Title | Percentage of Participants by Their Choice of Treatment in the Treatment Continuation Period (PH FDC SC or P+H IV) and by Consistency of This Choice With Their Preferred Method of Administration Reported in Question 1 of the PPQ |
|---|---|
| Description | At treatment Cycle 7, participants were expected to select the study treatment formulation (PH FDC SC or P+H IV) to complete their 18 cycles of neo/adjuvant HER2-targeted treatment after completion of the Treatment Cross-over Period. Additionally, for each participant's preference category (SC, IV, and No preference) as per the question 1 of the patient preference questionnaire (PPQ), the percentage of participants who selected each treatment administration route for the Treatment Continuation Period (PH FDC SC or P+H IV) was summarized. |
| Time Frame | Cycle 7 Day 1 (each cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| All randomized participants, allocated to their randomized treatment arm. |
| Arm/Group Title | All Participants | A: P+H IV Followed by PH FDC SC | B: PH FDC SC Followed by P+H IV |
|---|---|---|---|
| Arm/Group Description | In the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
| Measure Participants | 160 | 80 | 80 |
| Chose PH FDC SC for Treatment Continuation |
86.9
108.6%
|
88.8
111%
|
85.0
53.1%
|
| Chose P+H IV for Treatment Continuation |
13.1
16.4%
|
11.3
14.1%
|
15.0
9.4%
|
| Preferred SC per the PPQ and Chose PH FDC SC for Continuation |
85.0
106.3%
|
87.5
109.4%
|
82.5
51.6%
|
| Preferred SC per the PPQ and Chose P+H IV for Continuation |
0.0
0%
|
0.0
0%
|
0.0
0%
|
| Preferred IV per the PPQ and Chose PH FDC SC for Continuation |
0.6
0.8%
|
1.3
1.6%
|
0.0
0%
|
| Preferred IV per the PPQ and Chose P+H IV for Continuation |
13.1
16.4%
|
11.3
14.1%
|
15.0
9.4%
|
| No Preference per the PPQ and Chose PH FDC SC for Continuation |
1.3
1.6%
|
0.0
0%
|
2.5
1.6%
|
| No Preference per the PPQ and Chose P+H IV for Continuation |
0.0
0%
|
0.0
0%
|
0.0
0%
|
| Title | Duration of Treatment Administration Activities According to Healthcare Professionals' Responses on Perception of Time by Treatment Cycle, Question 1 of the Healthcare Professional Questionnaire (HCPQ) - Treatment Room |
|---|---|
| Description | The Healthcare Professional Questionnaire (HCPQ)-Treatment Room Question 1 was completed at each treatment cycle of the Treatment Cross-Over Period by the healthcare professionals (HCPs) who administered treatment to the study's participants. HCPs responded to the following parts of Question 1 that sought to evaluate the amount of time it took to complete activities related to treatment administration: "If new IV access was needed for this cycle of treatment, please indicate what type of IV access was provided (central venous catheter, peripherally inserted central catheter, or peripheral vein cannulation) and how long (in minutes) this took to set up (only for participants receiving IV treatment)? How long (in minutes) did it take to administer the treatment, i.e. total infusion duration? How long (in minutes) was the patient in the Treatment Room for in total?" |
| Time Frame | Day 1 of Cycles 1-6 (each cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| The number analyzed includes HCPs who completed question 1 of the survey per treatment cycle. For the questions related to IV access, the number analyzed only includes HCP responses for participants who required new IV access at a given treatment cycle. |
| Arm/Group Title | A: P+H IV Followed by PH FDC SC | B: PH FDC SC Followed by P+H IV |
|---|---|---|
| Arm/Group Description | In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
| Measure Participants | 80 | 80 |
| Cycle 1. Duration of Central Venous Catheter Set Up (IV Only)? |
5.0
|
|
| Cycle 1. Duration of Peripherally Inserted Central Catheter Set Up (IV Only)? |
5.0
|
|
| Cycle 1. Duration of Peripheral Vein Cannulation Set Up (IV Only)? |
5.0
|
|
| Cycle 1. How Long Did it Take to Administer the Treatment? |
150.0
|
8.0
|
| Cycle 1. How Long Was the Patient in the Treatment Room in Total? |
300.0
|
50.0
|
| Cycle 2. Duration of Central Venous Catheter Set Up (IV Only)? |
5.0
|
|
| Cycle 2. Duration of Peripherally Inserted Central Catheter Set Up (IV Only)? |
3.0
|
|
| Cycle 2. Duration of Peripheral Vein Cannulation Set Up (IV Only)? |
5.0
|
|
| Cycle 2. How Long Did it Take to Administer the Treatment? |
90.0
|
8.0
|
| Cycle 2. How Long Was the Patient in the Treatment Room in Total? |
153.0
|
40.0
|
| Cycle 3. Duration of Central Venous Catheter Set Up (IV Only)? |
5.0
|
|
| Cycle 3. Duration of Peripherally Inserted Central Catheter Set Up (IV Only)? |
3.0
|
|
| Cycle 3. Duration of Peripheral Vein Cannulation Set Up (IV Only)? |
5.0
|
|
| Cycle 3. How Long Did it Take to Administer the Treatment? |
70.0
|
7.5
|
| Cycle 3. How Long Was the Patient in the Treatment Room in Total? |
150.0
|
36.0
|
| Cycle 4. Duration of Central Venous Catheter Set Up (IV Only)? |
5.0
|
|
| Cycle 4. Duration of Peripherally Inserted Central Catheter Set Up (IV Only)? |
42.0
|
|
| Cycle 4. Duration of Peripheral Vein Cannulation Set Up (IV Only)? |
5.0
|
|
| Cycle 4. How Long Did it Take to Administer the Treatment? |
8.0
|
60.0
|
| Cycle 4. How Long Was the Patient in the Treatment Room in Total? |
45.0
|
150.0
|
| Cycle 5. Duration of Central Venous Catheter Set Up (IV Only)? |
3.0
|
|
| Cycle 5. Duration of Peripherally Inserted Central Catheter Set Up (IV Only)? |
10.0
|
|
| Cycle 5. Duration of Peripheral Vein Cannulation Set Up (IV Only)? |
5.0
|
|
| Cycle 5. How Long Did it Take to Administer the Treatment? |
8.0
|
83.0
|
| Cycle 5. How Long Was the Patient in the Treatment Room in Total? |
33.0
|
150.0
|
| Cycle 6. Duration of Central Venous Catheter Set Up (IV Only)? |
10.0
|
|
| Cycle 6. Duration of Peripheral Vein Cannulation Set Up (IV Only)? |
5.0
|
|
| Cycle 6. How Long Did it Take to Administer the Treatment? |
7.0
|
60.0
|
| Cycle 6. How Long Was the Patient in the Treatment Room in Total? |
35.0
|
130.0
|
| Title | Percentage of Healthcare Professionals (HCPs) by Their Responses on Perception of Impact of PH FDC SC on Clinical Management and Clinical Efficiency, Question 2 of the HCPQ - Treatment Room |
|---|---|
| Description | HCPs who administered study treatment responded at Cycle 6 of the Treatment Cross-Over Period to the following HCPQ-Treatment Room Question 2: "If all P+H IV infusions are switched to FDC SC injections, please indicate how strongly you agree or disagree with each of the following statements: a) Patients will be moved outside of infusion unit to receive FDC SC; b) FDC SC route will allow more flexible scheduling; c) More patients will be treated in the infusion unit; d) Waiting list for any P+H IV treatment at the infusion unit will be reduced; e) Staff resources will be redistributed to other departments of the hospital; f) There will still be sufficient interaction time between HCPs and patients; g) Staff will spend more time for further education/development; h) Staff will dedicate more time attending to administrative tasks for Perjeta-Herceptin patients; i) Patients will spend less time in the care unit; j) Administration by FDC SC injection is preferred by patients." |
| Time Frame | Day 1 of Cycle 6 (each cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| The number analyzed includes healthcare professionals (HCPs) who completed any part of the survey at treatment Cycle 6. |
| Arm/Group Title | All Healthcare Professionals | A: P+H IV Followed by PH FDC SC | B: PH FDC SC Followed by P+H IV |
|---|---|---|---|
| Arm/Group Description | This analysis set includes all healthcare professionals who treated participants from Arms A and B and completed the HCPQ questionnaire, which was administered at the last treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
| Measure Participants | 159 | 79 | 80 |
| Statement a): Strongly Disagree |
16.4
|
11.4
|
21.3
|
| Statement a): Disagree |
15.1
|
12.7
|
17.5
|
| Statement a): Neutral |
6.3
|
8.9
|
3.8
|
| Statement a): Agree |
21.4
|
26.6
|
16.3
|
| Statement a): Strongly Agree |
22.6
|
22.8
|
22.5
|
| Statement a): Not Applicable |
12.6
|
13.9
|
11.3
|
| Statement a): Answer Missing |
5.7
|
3.8
|
7.5
|
| Statement b): Strongly Disagree |
3.1
|
0.0
|
6.3
|
| Statement b): Disagree |
8.8
|
7.6
|
10.0
|
| Statement b): Neutral |
8.8
|
10.1
|
7.5
|
| Statement b): Agree |
28.3
|
29.1
|
27.5
|
| Statement b): Strongly Agree |
45.3
|
49.4
|
41.3
|
| Statement b): Not Applicable |
0.0
|
0.0
|
0.0
|
| Statement b): Answer Missing |
5.7
|
3.8
|
7.5
|
| Statement c): Strongly Disagree |
2.5
|
1.3
|
3.8
|
| Statement c): Disagree |
7.5
|
7.6
|
7.5
|
| Statement c): Neutral |
15.1
|
17.7
|
12.5
|
| Statement c): Agree |
30.2
|
29.1
|
31.3
|
| Statement c): Strongly Agree |
37.1
|
36.7
|
37.5
|
| Statement c): Not Applicable |
1.9
|
3.8
|
0.0
|
| Statement c): Answer Missing |
5.7
|
3.8
|
7.5
|
| Statement d): Strongly Disagree |
4.4
|
1.3
|
7.5
|
| Statement d): Disagree |
8.2
|
8.9
|
7.5
|
| Statement d): Neutral |
14.5
|
17.7
|
11.3
|
| Statement d): Agree |
27.7
|
29.1
|
26.3
|
| Statement d): Strongly Agree |
35.2
|
36.7
|
33.8
|
| Statement d): Not Applicable |
3.8
|
2.5
|
5.0
|
| Statement d): Answer Missing |
6.3
|
3.8
|
8.8
|
| Statement e): Strongly Disagree |
12.6
|
15.2
|
10.0
|
| Statement e): Disagree |
19.5
|
16.5
|
22.5
|
| Statement e): Neutral |
20.1
|
17.7
|
22.5
|
| Statement e): Agree |
15.1
|
19.0
|
11.3
|
| Statement e): Strongly Agree |
19.5
|
20.3
|
18.8
|
| Statement e): Not Applicable |
6.9
|
7.6
|
6.3
|
| Statement e): Answer Missing |
6.3
|
3.8
|
8.8
|
| Statement f): Strongly Disagree |
1.9
|
0.0
|
3.8
|
| Statement f): Disagree |
5.0
|
6.3
|
3.8
|
| Statement f): Neutral |
15.7
|
15.2
|
16.3
|
| Statement f): Agree |
32.1
|
31.6
|
32.5
|
| Statement f): Strongly Agree |
39.0
|
43.0
|
35.0
|
| Statement f): Not Applicable |
0.0
|
0.0
|
0.0
|
| Statement f): Answer Missing |
6.3
|
3.8
|
8.8
|
| Statement g): Strongly Disagree |
2.5
|
0.0
|
5.0
|
| Statement g): Disagree |
9.4
|
7.6
|
11.3
|
| Statement g): Neutral |
27.7
|
31.6
|
23.8
|
| Statement g): Agree |
21.4
|
20.3
|
22.5
|
| Statement g): Strongly Agree |
31.4
|
35.4
|
27.5
|
| Statement g): Not Applicable |
1.9
|
1.3
|
2.5
|
| Statement g): Answer Missing |
5.7
|
3.8
|
7.5
|
| Statement h): Strongly Disagree |
3.1
|
1.3
|
5.0
|
| Statement h): Disagree |
13.8
|
11.4
|
16.3
|
| Statement h): Neutral |
24.5
|
25.3
|
23.8
|
| Statement h): Agree |
20.1
|
24.1
|
16.3
|
| Statement h): Strongly Agree |
30.2
|
32.9
|
27.5
|
| Statement h): Not Applicable |
2.5
|
1.3
|
3.8
|
| Statement h): Answer Missing |
5.7
|
3.8
|
7.5
|
| Statement i): Strongly Disagree |
0.0
|
0.0
|
0.0
|
| Statement i): Disagree |
5.0
|
6.3
|
3.8
|
| Statement i): Neutral |
3.1
|
1.3
|
5.0
|
| Statement i): Agree |
25.2
|
27.8
|
22.5
|
| Statement i): Strongly Agree |
60.4
|
60.8
|
60.0
|
| Statement i): Not Applicable |
0.0
|
0.0
|
0.0
|
| Statement i): Answer Missing |
6.3
|
3.8
|
8.8
|
| Statement j): Strongly Disagree |
0.0
|
0.0
|
0.0
|
| Statement j): Disagree |
5.0
|
8.9
|
1.3
|
| Statement j): Neutral |
12.6
|
10.1
|
15.0
|
| Statement j): Agree |
24.5
|
22.8
|
26.3
|
| Statement j): Strongly Agree |
50.3
|
53.2
|
47.5
|
| Statement j): Not Applicable |
1.3
|
1.3
|
1.3
|
| Statement j): Answer Missing |
6.3
|
3.8
|
8.8
|
| Title | Percentage of Healthcare Professionals (HCPs) by Their Responses on Perception of Time/Resource Use and Convenience of Each Study Regimen, Questions 3 to 7 of the HCPQ - Treatment Room |
|---|---|
| Description | Healthcare professionals (HCPs) who administered study treatment responded at Cycle 6 of the Treatment Cross-Over Period to the following HCPQ-Treatment Room Questions 3 to 7: "Looking back over the Perjeta-Herceptin treatment sessions, please indicate based on your opinion which administration method: Q3. Which Method Was Most Convenient for the Patient? Q4. Which Method Was Best for Optimizing Patient Care in Your Centre? Q5. Which Method Took the Least Time from Start to Finish of Administration? Q6. Which Method Required the Least Resource Use for Administration? Q7. Which Method Was Preferred by Patients?" The four available response options were: P+H IV, FDC SC, No Difference, and Unsure. |
| Time Frame | Day 1 of Cycle 6 (each cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| The number analyzed includes HCPs who completed any part of the survey at treatment Cycle 6. |
| Arm/Group Title | All Healthcare Professionals | A: P+H IV Followed by PH FDC SC | B: PH FDC SC Followed by P+H IV |
|---|---|---|---|
| Arm/Group Description | This analysis set includes all healthcare professionals who treated participants from Arms A and B and completed the HCPQ questionnaire, which was administered at the last treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
| Measure Participants | 159 | 79 | 80 |
| Q3. Answer: FDC SC |
86.8
|
88.6
|
85.0
|
| Q3. Answer: P+H IV |
3.8
|
6.3
|
1.3
|
| Q3. Answer: No Difference |
3.8
|
2.5
|
5.0
|
| Q3. Answer: Unsure |
3.8
|
0.0
|
7.5
|
| Q3. Answer: Missing |
1.9
|
2.5
|
1.3
|
| Q4. Answer: FDC SC |
79.2
|
79.7
|
78.8
|
| Q4. Answer: P+H IV |
2.5
|
3.8
|
1.3
|
| Q4. Answer: No Difference |
12.6
|
12.7
|
12.5
|
| Q4. Answer: Unsure |
3.8
|
1.3
|
6.3
|
| Q4. Answer: Missing |
1.9
|
2.5
|
1.3
|
| Q5. Answer: FDC SC |
95.6
|
94.9
|
96.3
|
| Q5. Answer: P+H IV |
0.0
|
0.0
|
0.0
|
| Q5. Answer: No Difference |
2.5
|
2.5
|
2.5
|
| Q5. Answer: Unsure |
0.0
|
0.0
|
0.0
|
| Q5. Answer: Missing |
1.9
|
2.5
|
1.3
|
| Q6. Answer: FDC SC |
86.2
|
83.5
|
88.8
|
| Q6. Answer: P+H IV |
0.6
|
0.0
|
1.3
|
| Q6. Answer: No Difference |
11.3
|
13.9
|
8.8
|
| Q6. Answer: Unsure |
0.0
|
0.0
|
0.0
|
| Q6. Answer: Missing |
1.9
|
2.5
|
1.3
|
| Q7. Answer: FDC SC |
77.4
|
77.2
|
77.5
|
| Q7. Answer: P+H IV |
6.3
|
7.6
|
5.0
|
| Q7. Answer: No Difference |
2.5
|
2.5
|
2.5
|
| Q7. Answer: Unsure |
11.9
|
10.1
|
13.8
|
| Q7. Answer: Missing |
1.9
|
2.5
|
1.3
|
| Title | Percentage of Healthcare Professionals (HCPs) by Their Responses to Question 8 of the HCPQ - Treatment Room |
|---|---|
| Description | Healthcare professionals (HCPs) who administered study treatment responded at Cycle 6 of the Treatment Cross-Over Period to the following HCPQ-Treatment Room Question 8: "How frequently would you offer or recommend FDC SC administration to your patients in the future?" The three available response options were: Always, Sometimes, and Never. |
| Time Frame | Day 1 of Cycle 6 (each cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| The number analyzed includes HCPs who completed any part of the survey at treatment Cycle 6. |
| Arm/Group Title | All Healthcare Professionals | A: P+H IV Followed by PH FDC SC | B: PH FDC SC Followed by P+H IV |
|---|---|---|---|
| Arm/Group Description | This analysis set includes all healthcare professionals who treated participants from Arms A and B and completed the HCPQ questionnaire, which was administered at the last treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
| Measure Participants | 159 | 79 | 80 |
| Always |
67.3
|
69.6
|
65.0
|
| Sometimes |
30.2
|
26.6
|
33.8
|
| Never |
0.6
|
1.3
|
0.0
|
| Missing |
1.9
|
2.5
|
1.3
|
| Title | Duration of Treatment Preparation According to Healthcare Professionals' Responses on Perception of Time by Treatment Cycle, Question 1 of the HCPQ - Drug Preparation Room |
|---|---|
| Description | The Healthcare Professional Questionnaire (HCPQ)-Drug Preparation Room Question 1 was completed at each treatment cycle of the Treatment Cross-Over Period by the healthcare professionals (HCPs) within the pharmacy/drug preparation area where pertuzumab IV and trastuzumab IV and pertuzumab and trastuzumab FDC SC were prepared and dispensed for treating the study's participants. HCPs responded to the following question: "How long (in minutes) did it take to prepare the treatment for use?" |
| Time Frame | Day 1 of Cycles 1-6 (each cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| The number analyzed includes healthcare professionals (HCPs) who completed question 1 of the survey per treatment cycle. |
| Arm/Group Title | A: P+H IV Followed by PH FDC SC | B: PH FDC SC Followed by P+H IV |
|---|---|---|
| Arm/Group Description | In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
| Measure Participants | 80 | 80 |
| Cycle 1 |
20.0
|
5.0
|
| Cycle 2 |
20.0
|
5.0
|
| Cycle 3 |
17.5
|
5.0
|
| Cycle 4 |
5.0
|
15.0
|
| Cycle 5 |
5.0
|
15.0
|
| Cycle 6 |
5.0
|
15.0
|
| Title | Percentage of Healthcare Professionals (HCPs) by Their Responses on Perception of Impact of PH FDC SC on Clinical Management and Clinical Efficiency, Question 2 of the HCPQ - Drug Preparation Room |
|---|---|
| Description | Healthcare professionals (HCPs) who prepared study treatment within the pharmacy/drug preparation area responded at Cycle 6 of the Treatment Cross-Over Period to the following HCPQ-Drug Preparation Room Question 2: "If all P+H IV infusions are switched to FDC SC injections, please indicate how strongly you agree or disagree with each of the following statements: a) Staff will have increased availability for other tasks in the pharmacy; b) Administrative procedures around FDC SC will require less time; c) FDC SC formulations will provide more flexibility for staff in managing their workload; d) Due to ready-to-use FDC SC formulations, potential dosing errors will be avoided; e) Due to ready-to-use FDC SC formulations, there will be less drug wastage; f) Without having to reconstitute the drug, less storage space for FDC SC related supplies will be required in the pharmacy; g) Preparation procedures and associated time staff time commitment will be reduced." |
| Time Frame | Day 1 of Cycle 6 (each cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| The number analyzed includes healthcare professionals (HCPs) who completed any part of the survey at treatment Cycle 6. |
| Arm/Group Title | All Healthcare Professionals | A: P+H IV Followed by PH FDC SC | B: PH FDC SC Followed by P+H IV |
|---|---|---|---|
| Arm/Group Description | This analysis set includes all healthcare professionals who treated participants from Arms A and B and completed the HCPQ questionnaire, which was administered at the last treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
| Measure Participants | 160 | 80 | 80 |
| Statement a): Strongly Disagree |
1.3
|
1.3
|
1.3
|
| Statement a): Disagree |
0.6
|
1.3
|
0.0
|
| Statement a): Neutral |
7.5
|
8.8
|
6.3
|
| Statement a): Agree |
28.8
|
28.8
|
28.8
|
| Statement a): Strongly Agree |
50.6
|
52.5
|
48.8
|
| Statement a): Not Applicable |
2.5
|
3.8
|
1.3
|
| Statement a): Answer Missing |
8.8
|
3.8
|
13.8
|
| Statement b): Strongly Disagree |
5.6
|
8.8
|
2.5
|
| Statement b): Disagree |
3.8
|
3.8
|
3.8
|
| Statement b): Neutral |
14.4
|
16.3
|
12.5
|
| Statement b): Agree |
18.1
|
17.5
|
18.8
|
| Statement b): Strongly Agree |
46.3
|
46.3
|
46.3
|
| Statement b): Not Applicable |
2.5
|
2.5
|
2.5
|
| Statement b): Answer Missing |
9.4
|
5.0
|
13.8
|
| Statement c): Strongly Disagree |
0.6
|
0.0
|
1.3
|
| Statement c): Disagree |
0.6
|
0.0
|
1.3
|
| Statement c): Neutral |
13.1
|
15.0
|
11.3
|
| Statement c): Agree |
26.3
|
28.8
|
23.8
|
| Statement c): Strongly Agree |
48.8
|
50.0
|
47.5
|
| Statement c): Not Applicable |
1.3
|
1.3
|
1.3
|
| Statement c): Answer Missing |
9.4
|
5.0
|
13.8
|
| Statement d): Strongly Disagree |
1.3
|
1.3
|
1.3
|
| Statement d): Disagree |
3.8
|
1.3
|
6.3
|
| Statement d): Neutral |
5.6
|
5.0
|
6.3
|
| Statement d): Agree |
23.1
|
26.3
|
20.0
|
| Statement d): Strongly Agree |
56.3
|
60.0
|
52.5
|
| Statement d): Not Applicable |
1.3
|
1.3
|
1.3
|
| Statement d): Answer Missing |
8.8
|
5.0
|
12.5
|
| Statement e): Strongly Disagree |
1.3
|
1.3
|
1.3
|
| Statement e): Disagree |
1.9
|
1.3
|
2.5
|
| Statement e): Neutral |
8.8
|
11.3
|
6.3
|
| Statement e): Agree |
21.9
|
21.3
|
22.5
|
| Statement e): Strongly Agree |
55.0
|
58.8
|
51.3
|
| Statement e): Not Applicable |
1.9
|
1.3
|
2.5
|
| Statement e): Answer Missing |
9.4
|
5.0
|
13.8
|
| Statement f): Strongly Disagree |
0.6
|
0.0
|
1.3
|
| Statement f): Disagree |
4.4
|
3.8
|
5.0
|
| Statement f): Neutral |
11.9
|
16.3
|
7.5
|
| Statement f): Agree |
24.4
|
20.0
|
28.8
|
| Statement f): Strongly Agree |
48.1
|
53.8
|
42.5
|
| Statement f): Not Applicable |
1.3
|
1.3
|
1.3
|
| Statement f): Answer Missing |
9.4
|
5.0
|
13.8
|
| Statement g): Strongly Disagree |
0.6
|
0.0
|
1.3
|
| Statement g): Disagree |
0.0
|
0.0
|
0.0
|
| Statement g): Neutral |
6.9
|
8.8
|
5.0
|
| Statement g): Agree |
31.3
|
30.0
|
32.5
|
| Statement g): Strongly Agree |
48.8
|
52.5
|
45.0
|
| Statement g): Not Applicable |
3.1
|
3.8
|
2.5
|
| Statement g): Answer Missing |
9.4
|
5.0
|
13.8
|
| Title | Percentage of Healthcare Professionals (HCPs) by Their Responses on Perception of Time/Resource Use of Each Study Regimen, Questions 3 and 4 of the HCPQ - Drug Preparation Room |
|---|---|
| Description | Healthcare professionals (HCPs) who prepared study treatment within the pharmacy/drug preparation area responded at Cycle 6 of the Treatment Cross-Over Period to the following HCPQ-Drug Preparation Room Questions 3 and 4: "Looking back over the Perjeta-Herceptin treatment sessions, please indicate based on your opinion which administration method: Q3. Was quickest from start to end of preparation to finish of administration (excluding observation period)?; Q4. Required less resource use for preparation and administration, for example nursing time, facility costs, equipment etc?" The three available response options were: P+H IV, FDC SC, and No Difference. |
| Time Frame | Day 1 of Cycle 6 (each cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| The number analyzed includes healthcare professionals (HCPs) who completed any part of the survey at treatment Cycle 6. |
| Arm/Group Title | All Healthcare Professionals | A: P+H IV Followed by PH FDC SC | B: PH FDC SC Followed by P+H IV |
|---|---|---|---|
| Arm/Group Description | This analysis set includes all healthcare professionals who treated participants from Arms A and B and completed the HCPQ questionnaire, which was administered at the last treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. | In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized. |
| Measure Participants | 160 | 80 | 80 |
| Q3. Answer: FDC SC |
87.5
|
92.5
|
82.5
|
| Q3. Answer: P+H IV |
0.6
|
0.0
|
1.3
|
| Q3. Answer: No Difference |
1.3
|
1.3
|
1.3
|
| Q3. Answer: Missing |
10.6
|
6.3
|
15.0
|
| Q4. Answer: FDC SC |
86.9
|
93.8
|
80.0
|
| Q4. Answer: P+H IV |
0.0
|
0.0
|
0.0
|
| Q4. Answer: No Difference |
2.5
|
0.0
|
5.0
|
| Q4. Answer: Missing |
10.6
|
6.3
|
15.0
|
| Title | Change From Baseline Over Time in Health-Related Quality of Life (HRQoL) as Assessed by the Global Health Status/QoL Scale Score of the the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC QLQ-C30) |
|---|---|
| Description | |
| Time Frame | Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Change From Baseline Over Time in the Physical Functioning Scale Score of the EORTC QLQ-C30 |
|---|---|
| Description | |
| Time Frame | Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Change From Baseline Over Time in the Role Functioning Scale Score of the EORTC QLQ-C30 |
|---|---|
| Description | |
| Time Frame | Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Change From Baseline Over Time in the Emotional Functioning Scale Score of the EORTC QLQ-C30 |
|---|---|
| Description | |
| Time Frame | Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Change From Baseline Over Time in the Cognitive Functioning Scale Score of the EORTC QLQ-C30 |
|---|---|
| Description | |
| Time Frame | Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Change From Baseline Over Time in the Social Functioning Scale Score of the EORTC QLQ-C30 |
|---|---|
| Description | |
| Time Frame | Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Change From Baseline Over Time in the Fatigue Scale Score of the EORTC QLQ-C30 |
|---|---|
| Description | |
| Time Frame | Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Change From Baseline Over Time in the Nausea and Vomiting Scale Score of the EORTC QLQ-C30 |
|---|---|
| Description | |
| Time Frame | Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Change From Baseline Over Time in the Pain Scale Score of the EORTC QLQ-C30 |
|---|---|
| Description | |
| Time Frame | Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Change From Baseline Over Time in the Dyspnoea Scale Score of the EORTC QLQ-C30 |
|---|---|
| Description | |
| Time Frame | Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Change From Baseline Over Time in the Insomnia Scale Score of the EORTC QLQ-C30 |
|---|---|
| Description | |
| Time Frame | Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Change From Baseline Over Time in the Appetite Loss Scale Score of the EORTC QLQ-C30 |
|---|---|
| Description | |
| Time Frame | Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Change From Baseline Over Time in the Constipation Scale Score of the EORTC QLQ-C30 |
|---|---|
| Description | |
| Time Frame | Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Change From Baseline Over Time in the Diarrhoea Scale Score of the EORTC QLQ-C30 |
|---|---|
| Description | |
| Time Frame | Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Change From Baseline Over Time in the Financial Difficulties Scale Score of the EORTC QLQ-C30 |
|---|---|
| Description | |
| Time Frame | Baseline (Day 1 of Cycle 1); Day 1 of Cycles 3, 6, and 15 (or last treatment cycle; each cycle is 21 days); 1.5, 2, and 3 years (up to 3 years) |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Safety Summary for Assessment of Switching Between the FDC SC and IV Formulations: Number of Participants With at Least One Adverse Event During the Treatment Cross-Over Period by Study Arm and Treatment Received |
|---|---|
| Description | Investigators used the NCI CTCAE v4.0 grading scale for assessing adverse event (AE) severity; if not listed, AE severity was graded as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe or medically significant; Grade 4 = life-threatening; Grade 5 = death related to AE. Severity and seriousness are not synonymous and investigators independently assessed these criteria for each AE. Investigators also determined whether an AE was considered to be related to the study drug. Adverse events to monitor were defined based on known risks associated with the study drugs and included: hypersensitivity reactions, administration-related reactions (ARRs), cardiac dysfunction, diarrhea grade ≥3, rash/skin reactions, mucositis, interstitial lung disease (ILD), (febrile) neutropenia, pulmonary events that may occur as a result of an ARR, and pregnancy/neonatal related. Multiple occurrences of AEs were counted only once per participant. LVEF = left ventricular ejection fraction |
| Time Frame | From Day 1 of Cycle 1 to the end of Cycle 3 of Cross-Over Period; from Day 1 of Cycle 4 to the end of Cycle 6 of Cross-Over Period (1 cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population: All participants who received at least one dose of any study treatment categorized according to the study treatment administered. In this analysis, participants are grouped by study arm and treatment received during the Cross-Over Period. |
| Arm/Group Title | Arm A: Treatment With P+H IV (Cycles 1 to 3) | Arm A: Treatment With PH FDC SC (Cycles 4 to 6) | Arm B: Treatment With PH FDC SC (Cycles 1 to 3) | Arm B: Treatment With P+H IV (Cycles 4 to 6) |
|---|---|---|---|---|
| Arm/Group Description | This safety analysis population only includes the adverse events that occurred in Arm A participants during treatment Cycles 1 to 3 when all Arm A participants were treated with P+H IV. In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received treatment with pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles and that was followed by treatment with pertuzumab and trastuzumab FDC SC (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). | This safety analysis population only includes adverse events that occurred in Arm A participants during treatment Cycles 4 to 6 when all Arm A participants were treated with PH FDC SC. In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received treatment with pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles and that was followed by treatment with pertuzumab and trastuzumab FDC SC (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). | This safety analysis population only includes adverse events that occurred in Arm B participants during treatment Cycles 1 to 3 when all Arm B participants were treated with PH FDC SC. In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received treatment with pertuzumab and trastuzumab FDC SC (PH FDC SC) for 3 treatment cycles and that was followed by treatment with pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles (1 cycle = 21 days). | This safety analysis population only includes adverse events that occurred in Arm B participants during treatment Cycles 4 to 6 when all Arm B participants were treated with P+H IV. In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received treatment with pertuzumab and trastuzumab FDC SC (PH FDC SC) for 3 treatment cycles and that was followed by treatment with pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles (1 cycle = 21 days). |
| Measure Participants | 80 | 80 | 80 | 80 |
| Any Adverse Event (AE) |
62
77.5%
|
58
72.5%
|
62
38.8%
|
51
NaN
|
| AE with Fatal Outcome |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Related AE with Fatal Outcome |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Grade 3 to 5 AE |
2
2.5%
|
1
1.3%
|
3
1.9%
|
4
NaN
|
| Related Grade 3 to 5 AE |
1
1.3%
|
0
0%
|
1
0.6%
|
0
NaN
|
| Cardiac AE (Including LVEF Events) |
1
1.3%
|
2
2.5%
|
3
1.9%
|
2
NaN
|
| Serious AE |
1
1.3%
|
1
1.3%
|
1
0.6%
|
5
NaN
|
| Anaphylaxis and Hypersensitivity AE, All Grades |
0
0%
|
2
2.5%
|
1
0.6%
|
0
NaN
|
| Anaphylaxis and Hypersensitivity AE, Grade ≥3 |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Administration Related Reaction (ARR), All Grades |
7
8.8%
|
14
17.5%
|
23
14.4%
|
2
NaN
|
| Administration Related Reaction (ARR), Grade ≥3 |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Cardiac Dysfunction AE, All Grades |
2
2.5%
|
1
1.3%
|
3
1.9%
|
3
NaN
|
| Cardiac Dysfunction AE, Grade ≥3 |
1
1.3%
|
0
0%
|
0
0%
|
0
NaN
|
| Diarrhea Grade ≥3 |
0
0%
|
0
0%
|
1
0.6%
|
0
NaN
|
| Rash/Skin Reactions |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Mucositis |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Pulmonary Events (ARR), All Grades |
18
22.5%
|
7
8.8%
|
4
2.5%
|
7
NaN
|
| Pulmonary Events (ARR), Grade ≥3 |
0
0%
|
0
0%
|
1
0.6%
|
0
NaN
|
| Pregnancy and Neonatal Related AEs, All Grades |
0
0%
|
0
0%
|
1
0.6%
|
0
NaN
|
| Pregnancy and Neonatal Related AEs, Grade ≥3 |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Interstitial Lung Disease (ILD) |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Neutropenia/Febrile Neutropenia, All Grades |
4
5%
|
1
1.3%
|
2
1.3%
|
4
NaN
|
| Neutropenia/Febrile Neutropenia, Grade ≥3 |
1
1.3%
|
0
0%
|
0
0%
|
0
NaN
|
| Local Infusion Site Reaction |
1
1.3%
|
0
0%
|
0
0%
|
0
NaN
|
| Systemic Infusion Site Reaction |
5
6.3%
|
0
0%
|
0
0%
|
1
NaN
|
| Local Injection Site Reaction |
0
0%
|
12
15%
|
24
15%
|
0
NaN
|
| Systemic Injection Site Reaction |
0
0%
|
2
2.5%
|
1
0.6%
|
0
NaN
|
| AE Leading to Any Study Treatment Discontinuation |
0
0%
|
1
1.3%
|
0
0%
|
0
NaN
|
| AE Leading to PH FDC SC Discontinuation |
0
0%
|
1
1.3%
|
0
0%
|
0
NaN
|
| AE Leading to Pertuzumab IV Discontinuation |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| AE Leading to Trastuzumab IV Discontinuation |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| AE Leading to Any Study Treatment Interruption or Dose Reduction |
1
1.3%
|
0
0%
|
2
1.3%
|
2
NaN
|
| Title | Safety Summary of the FDC SC and IV Formulations: Number of Participants With at Least One Adverse Event During the Treatment Cross-Over and Treatment Continuation Periods |
|---|---|
| Description | Investigators used the NCI CTCAE v4.0 grading scale for assessing adverse event (AE) severity; if not listed, AE severity was graded as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe or medically significant; Grade 4 = life-threatening; Grade 5 = death related to AE. Severity and seriousness are not synonymous and investigators independently assessed these criteria for each AE. Investigators also determined whether an AE was considered to be related to the study drug. Adverse events to monitor were defined based on known risks associated with the study drugs and included: hypersensitivity reactions, administration-related reactions (ARRs), cardiac dysfunction, diarrhea grade ≥3, rash/skin reactions, mucositis, interstitial lung disease (ILD), (febrile) neutropenia, pulmonary events that may occur as a result of an ARR, and pregnancy/neonatal related. Multiple occurrences of AEs were counted only once per participant. LVEF = left ventricular ejection fraction |
| Time Frame | From Day 1 of Cycle 1 of the Treatment Cross-Over Period up to the completion of 18 cycles of neo/adjuvant anti-HER2 treatment in the Treatment Continuation Period (1 cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population: All participants who received at least one dose of any study treatment categorized according to the study treatment administered. In this analysis, participants are grouped by treatment received during the Cross-Over and Continuation Periods. |
| Arm/Group Title | P+H IV: Treatment Cross-Over Period | PH FDC SC: Treatment Cross-Over Period | P+H IV: Treatment Continuation Period | PH FDC SC: Treatment Continuation Period |
|---|---|---|---|---|
| Arm/Group Description | This safety analysis population includes all participants from Arms A and B who received up to 3 cycles (1 cycle = 21 days) of treatment with pertuzumab IV and trastuzumab IV (P+H IV) during the Treatment Cross-Over Period of the study. | This safety analysis population includes all participants from Arms A and B who received up to 3 cycles (1 cycle = 21 days) of treatment with the pertuzumab and trastuzumab fixed-dose combination administered subcutaneously (PH FDC SC) during the Treatment Cross-Over Period of the study. | This safety analysis population includes all participants from Arms A and B who, following completion of the Treatment Cross-Over Period, chose to receive pertuzumab IV and trastuzumab IV (P+H IV) during the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). | This safety analysis population includes all participants from Arms A and B who, following completion of the Treatment Cross-Over Period, chose to receive the pertuzumab and trastuzumab fixed-dose combination administered subcutaneously (PH FDC SC) during the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). |
| Measure Participants | 160 | 160 | 21 | 137 |
| Any Adverse Event (AE) |
113
141.3%
|
120
150%
|
13
8.1%
|
70
NaN
|
| AE with Fatal Outcome |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Related AE with Fatal Outcome |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Grade 3 to 5 AE |
6
7.5%
|
4
5%
|
2
1.3%
|
4
NaN
|
| Related Grade 3 to 5 AE |
1
1.3%
|
1
1.3%
|
0
0%
|
0
NaN
|
| Cardiac AE (Including LVEF Events) |
3
3.8%
|
5
6.3%
|
0
0%
|
1
NaN
|
| Serious AE |
6
7.5%
|
2
2.5%
|
0
0%
|
3
NaN
|
| Anaphylaxis and Hypersensitivity AE, All Grades |
0
0%
|
3
3.8%
|
0
0%
|
2
NaN
|
| Anaphylaxis and Hypersensitivity AE, Grade ≥3 |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Administration Related Reaction AE, All Grades |
9
11.3%
|
38
47.5%
|
0
0%
|
13
NaN
|
| Administration Related Reaction AE, Grade ≥3 |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Cardiac Dysfunction AE, All Grades |
5
6.3%
|
4
5%
|
0
0%
|
3
NaN
|
| Cardiac Dysfunction AE, Grade ≥3 |
1
1.3%
|
0
0%
|
0
0%
|
0
NaN
|
| Diarrhea Grade ≥3 |
0
0%
|
1
1.3%
|
0
0%
|
0
NaN
|
| Rash/Skin Reactions |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Mucositis |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Pulmonary Events (ARR), All Grades |
25
31.3%
|
11
13.8%
|
3
1.9%
|
11
NaN
|
| Pulmonary Events (ARR), Grade ≥3 |
0
0%
|
1
1.3%
|
0
0%
|
0
NaN
|
| Pregnancy and Neonatal Related AEs, All Grades |
0
0%
|
1
1.3%
|
0
0%
|
0
NaN
|
| Pregnancy and Neonatal Related AEs, Grade ≥3 |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Interstitial Lung Disease (ILD), All Grades |
0
0%
|
0
0%
|
0
0%
|
1
NaN
|
| Interstitial Lung Disease (ILD), Grade ≥3 |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Neutropenia/Febrile Neutropenia, All Grades |
8
10%
|
3
3.8%
|
0
0%
|
3
NaN
|
| Neutropenia/Febrile Neutropenia, Grade ≥3 |
1
1.3%
|
0
0%
|
0
0%
|
1
NaN
|
| Local Infusion Site Reaction |
1
1.3%
|
0
0%
|
0
0%
|
0
NaN
|
| Systemic Infusion Site Reaction |
6
7.5%
|
0
0%
|
0
0%
|
0
NaN
|
| Local Injection Site Reaction |
0
0%
|
36
45%
|
0
0%
|
10
NaN
|
| Systemic Injection Site Reaction |
0
0%
|
3
3.8%
|
0
0%
|
2
NaN
|
| AE Leading to Any Study Treatment Discontinuation |
0
0%
|
1
1.3%
|
1
0.6%
|
0
NaN
|
| AE Leading to PH FDC SC Discontinuation |
0
0%
|
1
1.3%
|
0
0%
|
0
NaN
|
| AE Leading to Pertuzumab IV Discontinuation |
0
0%
|
0
0%
|
1
0.6%
|
0
NaN
|
| AE Leading to Trastuzumab IV Discontinuation |
0
0%
|
0
0%
|
1
0.6%
|
0
NaN
|
| AE Leading to Any Study Treatment Interruption or Dose Reduction |
3
3.8%
|
2
2.5%
|
1
0.6%
|
3
NaN
|
| Title | Number of Participants With at Least One Event of Heart Failure With the FDC SC and IV Formulations During the Treatment Cross-Over and Treatment Continuation Periods |
|---|---|
| Description | Heart failure is defined as a disorder characterized by the inability of the heart to pump blood at an adequate volume to meet tissue metabolic requirements, or, the ability to do only at an elevation in the filling pressure. Any adverse event of symptomatic left ventricular systolic dysfunction (LVSD; also referred to as heart failure) occurring during the study was to be reported as a serious adverse event. |
| Time Frame | From Day 1 of Cycle 1 of the Treatment Cross-Over Period up to the completion of 18 cycles of neo/adjuvant anti-HER2 treatment in the Treatment Continuation Period (1 cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population: All participants who received at least one dose of any study treatment categorized according to the study treatment administered. In this analysis, participants are grouped by treatment received during the Cross-Over and Continuation Periods. |
| Arm/Group Title | P+H IV: Treatment Cross-Over Period | PH FDC SC: Treatment Cross-Over Period | P+H IV: Treatment Continuation Period | PH FDC SC: Treatment Continuation Period |
|---|---|---|---|---|
| Arm/Group Description | This safety analysis population includes all participants from Arms A and B who received up to 3 cycles (1 cycle = 21 days) of treatment with pertuzumab IV and trastuzumab IV (P+H IV) during the Treatment Cross-Over Period of the study. | This safety analysis population includes all participants from Arms A and B who received up to 3 cycles (1 cycle = 21 days) of treatment with the pertuzumab and trastuzumab fixed-dose combination administered subcutaneously (PH FDC SC) during the Treatment Cross-Over Period of the study. | This safety analysis population includes all participants from Arms A and B who, following completion of the Treatment Cross-Over Period, chose to receive pertuzumab IV and trastuzumab IV (P+H IV) during the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). | This safety analysis population includes all participants from Arms A and B who, following completion of the Treatment Cross-Over Period, chose to receive the pertuzumab and trastuzumab fixed-dose combination administered subcutaneously (PH FDC SC) during the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). |
| Measure Participants | 160 | 160 | 21 | 137 |
| Count of Participants [Participants] |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Title | Number of Participants With at Least One Event of Ejection Fraction Decreased With the FDC SC and IV Formulations During the Treatment Cross-Over and Treatment Continuation Periods |
|---|---|
| Description | Left ventricular ejection fraction (LVEF) is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. All participants who enrolled in this study must have had a baseline LVEF ≥55%. Verbatim description of adverse events was mapped to Medical Dictionary for Regulatory Activities (MedDRA) version 22.1. The MedDRA preferred term of 'ejection fraction decreased' is defined as an LVEF decrease of at least 10 percentage points from baseline and to below 50%. |
| Time Frame | Baseline; Day 1 of Cycles 4, 7, and 11 (each cycle is 21 days); End of Treatment and Follow-Up visits (up to 3 years) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population: All participants who received at least one dose of any study treatment categorized according to the study treatment administered. In this analysis, participants are grouped by treatment received during the Cross-Over and Continuation Periods. |
| Arm/Group Title | P+H IV: Treatment Cross-Over Period | PH FDC SC: Treatment Cross-Over Period | P+H IV: Treatment Continuation Period | PH FDC SC: Treatment Continuation Period |
|---|---|---|---|---|
| Arm/Group Description | This safety analysis population includes all participants from Arms A and B who received up to 3 cycles (1 cycle = 21 days) of treatment with pertuzumab IV and trastuzumab IV (P+H IV) during the Treatment Cross-Over Period of the study. | This safety analysis population includes all participants from Arms A and B who received up to 3 cycles (1 cycle = 21 days) of treatment with the pertuzumab and trastuzumab fixed-dose combination administered subcutaneously (PH FDC SC) during the Treatment Cross-Over Period of the study. | This safety analysis population includes all participants from Arms A and B who, following completion of the Treatment Cross-Over Period, chose to receive pertuzumab IV and trastuzumab IV (P+H IV) during the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). | This safety analysis population includes all participants from Arms A and B who, following completion of the Treatment Cross-Over Period, chose to receive the pertuzumab and trastuzumab fixed-dose combination administered subcutaneously (PH FDC SC) during the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). |
| Measure Participants | 160 | 160 | 21 | 137 |
| Count of Participants [Participants] |
3
3.8%
|
4
5%
|
0
0%
|
0
NaN
|
| Title | Number of Participants With Targeted Vital Signs Outside the Normal Limits During the Treatment Cross-Over Period Among Those Without an Abnormality at Baseline |
|---|---|
| Description | The number of participants at any post-baseline timepoint with abnormal readings outside the normal range for vital signs of diastolic and systolic blood pressure, pulse rate, respiratory rate, and body temperature were summarized according the specified direction of the abnormal reading (high or low). The number analyzed (denominator) in the results table represents participants without the specified abnormal vital sign at baseline. Not every vital sign abnormality qualified as an adverse event (AE). A vital sign result must have been reported as an AE if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation); resulted in a medical intervention or a change in concomitant therapy; or, was clinically significant in the investigator's judgment. |
| Time Frame | Pre-dose at Day 1 of Cycles 1 (baseline), 4, and 7 (1 cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population: All participants who received at least one dose of any study treatment categorized according to the study treatment administered. In this analysis, participants are grouped by study arm and treatment received during the Cross-Over Period. The number analyzed (denominator) represents those without an abnormality at baseline. |
| Arm/Group Title | Arm A: Treatment With P+H IV (Cycles 1 to 3) | Arm A: Treatment With PH FDC SC (Cycles 4 to 6) | Arm B: Treatment With PH FDC SC (Cycles 1 to 3) | Arm B: Treatment With P+H IV (Cycles 4 to 6) |
|---|---|---|---|---|
| Arm/Group Description | This safety analysis population only includes the safety data that was collected from Arm A participants during treatment Cycles 1 to 3 when all Arm A participants were treated with P+H IV. In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received treatment with pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles and that was followed by treatment with pertuzumab and trastuzumab FDC SC (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). | This safety analysis population only includes the safety data that was collected from Arm A participants during treatment Cycles 4 to 6 when all Arm A participants were treated with PH FDC SC. In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received treatment with pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles and that was followed by treatment with pertuzumab and trastuzumab FDC SC (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). | This safety analysis population only includes the safety data that was collected from Arm B participants during treatment Cycles 1 to 3 when all Arm B participants were treated with PH FDC SC. In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received treatment with pertuzumab and trastuzumab FDC SC (PH FDC SC) for 3 treatment cycles and that was followed by treatment with pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles (1 cycle = 21 days). | This safety analysis population only includes the safety data that was collected from Arm B participants during treatment Cycles 4 to 6 when all Arm B participants were treated with P+H IV. In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received treatment with pertuzumab and trastuzumab FDC SC (PH FDC SC) for 3 treatment cycles and that was followed by treatment with pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles (1 cycle = 21 days). |
| Measure Participants | 80 | 80 | 80 | 80 |
| Diastolic Blood Pressure - Low |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Diastolic Blood Pressure - High |
2
2.5%
|
2
2.5%
|
0
0%
|
0
NaN
|
| Systolic Blood Pressure - Low |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Systolic Blood Pressure - High |
8
10%
|
7
8.8%
|
3
1.9%
|
3
NaN
|
| Pulse Rate - Low |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Pulse Rate - High |
1
1.3%
|
0
0%
|
0
0%
|
1
NaN
|
| Respiratory Rate - Low |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Respiratory Rate - High |
1
1.3%
|
0
0%
|
2
1.3%
|
2
NaN
|
| Temperature - Low |
21
26.3%
|
16
20%
|
10
6.3%
|
13
NaN
|
| Temperature - High |
0
0%
|
0
0%
|
1
0.6%
|
0
NaN
|
| Title | Number of Participants With Chemistry and Hematology Laboratory Test Result Shifts From NCI-CTCAE Grade 0-2 at Baseline to Grade 3-4 Post-Baseline During the Treatment Cross-Over Period |
|---|---|
| Description | Laboratory data for targeted chemistry and hematology parameters were classified according to the NCI CTCAE v4.0; Grade 0 is normal and Grades 1 to 4 represent worsening levels of the parameter outside of the normal range in the specified direction of the abnormality (high and low are above and below the range, respectively). The results show the shifts in the number of participants with Grade 0-2 at baseline to Grade 3-4 post-baseline; those with missing baseline values were counted as Grade 0-2 at baseline. Not every laboratory abnormality qualified as an adverse event, only if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation); resulted in a medical intervention or a change in concomitant therapy; or, was clinically significant in the investigator's judgment. SGOT/AST = aspartate aminotransferase; SGPT/ALT = alanine aminotransferase |
| Time Frame | Pre-dose at Day 1 of Cycles 1 (baseline), 4, and 7 (1 cycle is 21 days) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Safety Population: All participants who received at least one dose of any study treatment categorized according to the study treatment administered. In this analysis, participants are grouped by study arm and treatment received during the Cross-Over Period. The number analyzed (denominator) represents those with NCI-CTCAE Grade 0-2 at baseline and at least one post-baseline assessment. |
| Arm/Group Title | Arm A: Treatment With P+H IV (Cycles 1 to 3) | Arm A: Treatment With PH FDC SC (Cycles 4 to 6) | Arm B: Treatment With PH FDC SC (Cycles 1 to 3) | Arm B: Treatment With P+H IV (Cycles 4 to 6) |
|---|---|---|---|---|
| Arm/Group Description | This safety analysis population only includes the safety data that was collected from Arm A participants during treatment Cycles 1 to 3 when all Arm A participants were treated with P+H IV. In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received treatment with pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles and that was followed by treatment with pertuzumab and trastuzumab FDC SC (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). | This safety analysis population only includes the safety data that was collected from Arm A participants during treatment Cycles 4 to 6 when all Arm A participants were treated with PH FDC SC. In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received treatment with pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles and that was followed by treatment with pertuzumab and trastuzumab FDC SC (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). | This safety analysis population only includes the safety data that was collected from Arm B participants during treatment Cycles 1 to 3 when all Arm B participants were treated with PH FDC SC. In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received treatment with pertuzumab and trastuzumab FDC SC (PH FDC SC) for 3 treatment cycles and that was followed by treatment with pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles (1 cycle = 21 days). | This safety analysis population only includes the safety data that was collected from Arm B participants during treatment Cycles 4 to 6 when all Arm B participants were treated with P+H IV. In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received treatment with pertuzumab and trastuzumab FDC SC (PH FDC SC) for 3 treatment cycles and that was followed by treatment with pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles (1 cycle = 21 days). |
| Measure Participants | 80 | 80 | 80 | 80 |
| Alkaline Phosphatase - High |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| SGPT/ALT - High |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| SGOT/AST - High |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Creatinine - High |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Bilirubin, Total - High |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Hemoglobin - Low |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Hemoglobin - High |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Neutrophils, Total, Abs - Low |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Platelet - Low |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Total Leukocyte Count - Low |
1
1.3%
|
0
0%
|
0
0%
|
0
NaN
|
| Total Leukocyte Count - High |
0
0%
|
0
0%
|
0
0%
|
0
NaN
|
| Title | Kaplan-Meier Estimate of the Percentage of Participants in Overall Survival |
|---|---|
| Description | |
| Time Frame | Up to 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Kaplan-Meier Estimate of the Percentage of Participants in Invasive Disease-Free Survival Including Second Primary Non-Breast Cancer |
|---|---|
| Description | |
| Time Frame | Up to 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Kaplan-Meier Estimate of the Percentage of Participants in Invasive Disease-Free Survival |
|---|---|
| Description | |
| Time Frame | Up to 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
| Title | Kaplan-Meier Estimate of the Percentage of Participants in Distant Disease-Free Survival |
|---|---|
| Description | |
| Time Frame | Up to 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title |
|---|
| Arm/Group Description |
Adverse Events
| Time Frame | From Baseline until 7 months after the last dose of study drug (up to 1 year, 2 months) | |||||||
|---|---|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | ||||||||
| Arm/Group Title | P+H IV: Treatment Cross-Over Period | PH FDC SC: Treatment Cross-Over Period | P+H IV: Treatment Continuation Period | PH FDC SC: Treatment Continuation Period | ||||
| Arm/Group Description | This safety analysis population includes all participants from Arms A and B who received up to 3 cycles (1 cycle = 21 days) of treatment with pertuzumab IV and trastuzumab IV (P+H IV) during the Treatment Cross-Over Period of the study. | This safety analysis population includes all participants from Arms A and B who received up to 3 cycles (1 cycle = 21 days) of treatment with the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) during the Treatment Cross-Over Period of the study. | This safety analysis population includes all participants from Arms A and B who, following completion of the Treatment Cross-Over Period, chose to receive pertuzumab IV and trastuzumab IV (P+H IV) during the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). | This safety analysis population includes all participants from Arms A and B who, following completion of the Treatment Cross-Over Period, chose to receive the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) during the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). | ||||
All Cause Mortality |
||||||||
| P+H IV: Treatment Cross-Over Period | PH FDC SC: Treatment Cross-Over Period | P+H IV: Treatment Continuation Period | PH FDC SC: Treatment Continuation Period | |||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/160 (0%) | 0/160 (0%) | 0/21 (0%) | 0/137 (0%) | ||||
Serious Adverse Events |
||||||||
| P+H IV: Treatment Cross-Over Period | PH FDC SC: Treatment Cross-Over Period | P+H IV: Treatment Continuation Period | PH FDC SC: Treatment Continuation Period | |||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 6/160 (3.8%) | 2/160 (1.3%) | 0/21 (0%) | 3/137 (2.2%) | ||||
| Infections and infestations | ||||||||
| Device related infection | 1/160 (0.6%) | 1 | 0/160 (0%) | 0 | 0/21 (0%) | 0 | 1/137 (0.7%) | 1 |
| Erysipelas | 1/160 (0.6%) | 1 | 0/160 (0%) | 0 | 0/21 (0%) | 0 | 1/137 (0.7%) | 1 |
| Breast cellulitis | 1/160 (0.6%) | 1 | 0/160 (0%) | 0 | 0/21 (0%) | 0 | 0/137 (0%) | 0 |
| Bronchopulmonary aspergillosis | 0/160 (0%) | 0 | 0/160 (0%) | 0 | 0/21 (0%) | 0 | 1/137 (0.7%) | 1 |
| Pneumonia | 1/160 (0.6%) | 1 | 0/160 (0%) | 0 | 0/21 (0%) | 0 | 0/137 (0%) | 0 |
| Upper respiratory tract infection | 1/160 (0.6%) | 1 | 0/160 (0%) | 0 | 0/21 (0%) | 0 | 0/137 (0%) | 0 |
| Investigations | ||||||||
| Ejection fraction decreased | 1/160 (0.6%) | 1 | 1/160 (0.6%) | 1 | 0/21 (0%) | 0 | 0/137 (0%) | 0 |
| Respiratory, thoracic and mediastinal disorders | ||||||||
| Asthma | 0/160 (0%) | 0 | 1/160 (0.6%) | 1 | 0/21 (0%) | 0 | 0/137 (0%) | 0 |
Other (Not Including Serious) Adverse Events |
||||||||
| P+H IV: Treatment Cross-Over Period | PH FDC SC: Treatment Cross-Over Period | P+H IV: Treatment Continuation Period | PH FDC SC: Treatment Continuation Period | |||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 57/160 (35.6%) | 77/160 (48.1%) | 8/21 (38.1%) | 29/137 (21.2%) | ||||
| Gastrointestinal disorders | ||||||||
| Diarrhoea | 16/160 (10%) | 19 | 13/160 (8.1%) | 17 | 4/21 (19%) | 4 | 14/137 (10.2%) | 20 |
| General disorders | ||||||||
| Fatigue | 9/160 (5.6%) | 9 | 9/160 (5.6%) | 9 | 1/21 (4.8%) | 2 | 4/137 (2.9%) | 4 |
| Injection site reaction | 0/160 (0%) | 0 | 36/160 (22.5%) | 50 | 0/21 (0%) | 0 | 10/137 (7.3%) | 25 |
| Injury, poisoning and procedural complications | ||||||||
| Radiation skin injury | 27/160 (16.9%) | 28 | 17/160 (10.6%) | 17 | 0/21 (0%) | 0 | 1/137 (0.7%) | 1 |
| Musculoskeletal and connective tissue disorders | ||||||||
| Arthralgia | 6/160 (3.8%) | 8 | 8/160 (5%) | 8 | 2/21 (9.5%) | 2 | 1/137 (0.7%) | 1 |
| Bone pain | 0/160 (0%) | 0 | 0/160 (0%) | 0 | 2/21 (9.5%) | 2 | 0/137 (0%) | 0 |
| Myalgia | 5/160 (3.1%) | 5 | 3/160 (1.9%) | 3 | 2/21 (9.5%) | 2 | 0/137 (0%) | 0 |
| Nervous system disorders | ||||||||
| Headache | 3/160 (1.9%) | 3 | 5/160 (3.1%) | 6 | 2/21 (9.5%) | 3 | 1/137 (0.7%) | 1 |
| Skin and subcutaneous tissue disorders | ||||||||
| Rash | 2/160 (1.3%) | 3 | 2/160 (1.3%) | 2 | 2/21 (9.5%) | 2 | 2/137 (1.5%) | 3 |
| Vascular disorders | ||||||||
| Hot flush | 6/160 (3.8%) | 6 | 9/160 (5.6%) | 10 | 0/21 (0%) | 0 | 3/137 (2.2%) | 3 |
Limitations/Caveats
[Not Specified]
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but only after the first publication or presentation that involves the overall study. The Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
Results Point of Contact
| Name/Title | Medical Communications |
|---|---|
| Organization | Hoffmann-La Roche |
| Phone | 800-821-8590 |
| genentech@druginfo.com |
Responsible Party:
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT03674112
Other Study ID Numbers:
- MO40628
- 2018-002153-30
First Posted:
Sep 17, 2018
Last Update Posted:
Apr 5, 2022
Last Verified:
Apr 1, 2022